Jacob, S. T. et al. Ebola virus disease. Nat. Rev. Dis. Prim. 6, 13 (2020).
Google Scholar
Kortepeter, M. G., Dierberg, K., Shenoy, E. S. & Cieslak, T. J. Marburg virus disease: A summary for clinicians. Int. J. Infect. Dis. 99, 233–242 (2020).
Google Scholar
Garry, R. F. Lassa fever – the road ahead. Nat. Rev. Microbiol 21, 87–96 (2023).
Google Scholar
Raabe, V., Mehta, A. K. & Evans, J. D. Lassa Virus Infection: a Summary for Clinicians. Int. J. Infect. Dis. 119, 187–200 (2022).
Google Scholar
Hawman, D. W. & Feldmann, H. Crimean-Congo haemorrhagic fever virus. Nat. Rev. Microbiol 21, 463–477 (2023).
Google Scholar
Connors, K. A. & Hartman, A. L. Advances in Understanding Neuropathogenesis of Rift Valley Fever Virus. Annu. Rev. Virol. 9, 437–450 (2022).
Google Scholar
Zhang, X. Y. et al. Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2. Infect. Dis. Poverty 9, 99 (2020).
Google Scholar
Hui, D. S. C. & Zumla, A. Severe Acute Respiratory Syndrome: Historical, Epidemiologic, and Clinical Features. Infect. Dis. Clin. North Am. 33, 869–889 (2019).
Google Scholar
de Wit, E., van Doremalen, N., Falzarano, D. & Munster, V. J. SARS and MERS: recent insights into emerging coronaviruses. Nat. Rev. Microbiol. 14, 523–534 (2016).
Google Scholar
Ang, B. S. P., Lim, T. C. C. & Wang, L. Nipah Virus Infection. J. Clin. Microbiol. 56, e01875–01817 (2018).
Google Scholar
Musso, D. & Gubler, D. J. Zika Virus. Clin. Microbiol. Rev. 29, 487–524 (2016).
Google Scholar
Fathi, A., Dahlke, C. & Addo, M. M. Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens. Hum. Vaccin Immunother. 15, 2269–2285 (2019).
Google Scholar
Friedrich, M. J. WHO’s Blueprint List of Priority Diseases. JAMA 319, 1973 (2018).
Google Scholar
Mehand, M. S., Al-Shorbaji, F., Millett, P. & Murgue, B. The WHO R&D Blueprint: 2018 review of emerging infectious diseases requiring urgent research and development efforts. Antivir. Res. 159, 63–67 (2018).
Google Scholar
Siragam, V., Wong, G. & Qiu, X. G. Animal models for filovirus infections. Zool. Res. 39, 15–24 (2018).
Google Scholar
Fan, C. et al. Animal models for COVID-19: advances, gaps and perspectives. Signal Transduct. Target Ther. 7, 220 (2022).
Google Scholar
Muñoz-Fontela, C. et al. Animal models for COVID-19. Nature 586, 509–515 (2020).
Google Scholar
Banadyga, L., Wong, G. & Qiu, X. Small Animal Models for Evaluating Filovirus Countermeasures. ACS Infect. Dis. 4, 673–685 (2018).
Google Scholar
Feldmann, H., Sprecher, A. & Geisbert, T. W. Ebola. N. Engl. J. Med. 382, 1832–1842 (2020).
Google Scholar
Ghosh, S., Saha, A., Samanta, S. & Saha, R. P. Genome structure and genetic diversity in the Ebola virus. Curr. Opin. Pharm. 60, 83–90 (2021).
Google Scholar
Milligan, J. C. et al. Asymmetric and non-stoichiometric glycoprotein recognition by two distinct antibodies results in broad protection against ebolaviruses. Cell 185, 995–1007.e18 (2022).
Google Scholar
Bär, S., Takada, A., Kawaoka, Y. & Alizon, M. Detection of cell-cell fusion mediated by Ebola virus glycoproteins. J. Virol. 80, 2815–2822 (2006).
Google Scholar
Beniac, D. R. & Booth, T. F. Structure of the Ebola virus glycoprotein spike within the virion envelope at 11Å resolution. Sci. Rep. 7, 46374 (2017).
Google Scholar
Kuroda, M. et al. Interaction between TIM-1 and NPC1 Is Important for Cellular Entry of Ebola Virus. J. Virol. 89, 6481–6493 (2015).
Google Scholar
Alvarez, C. P. et al. C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans. J. Virol. 76, 6841–6844 (2002).
Google Scholar
Shimojima, M. et al. Tyro3 family-mediated cell entry of Ebola and Marburg viruses. J. Virol. 80, 10109–10116 (2006).
Google Scholar
Geisbert, T. W. & Hensley, L. E. Ebola virus: new insights into disease aetiopathology and possible therapeutic interventions. Expert Rev. Mol. Med. 6, 1–24 (2004).
Google Scholar
Geisbert, T. W. et al. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am. J. Pathol. 163, 2347–2370 (2003).
Google Scholar
Lin, G. et al. Differential N-linked glycosylation of human immunodeficiency virus and Ebola virus envelope glycoproteins modulates interactions with DC-SIGN and DC-SIGNR. J. Virol. 77, 1337–1346 (2003).
Google Scholar
Takada, A. et al. Human macrophage C-type lectin specific for galactose and N-acetylgalactosamine promotes filovirus entry. J. Virol. 78, 2943–2947 (2004).
Google Scholar
Aleksandrowicz, P. et al. Ebola virus enters host cells by macropinocytosis and clathrin-mediated endocytosis. J. Infect. Dis. 204, S957–S967 (2011).
Google Scholar
Nanbo, A. et al. Ebolavirus is internalized into host cells via macropinocytosis in a viral glycoprotein-dependent manner. PLoS Pathog. 6, e1001121 (2010).
Google Scholar
Saeed, M. F., Kolokoltsov, A. A., Albrecht, T. & Davey, R. A. Cellular entry of ebola virus involves uptake by a macropinocytosis-like mechanism and subsequent trafficking through early and late endosomes. PLoS Pathog. 6, e1001110 (2010).
Google Scholar
Wang, H. et al. Ebola Viral Glycoprotein Bound to Its Endosomal Receptor Niemann-Pick C1. Cell 164, 258–268 (2016).
Google Scholar
Carette, J. E. et al. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature 477, 340–343 (2011).
Google Scholar
Olson, M. A., Lee, M. S. & Yeh, I. C. Membrane insertion of fusion peptides from Ebola and Marburg viruses studied by replica-exchange molecular dynamics simulations. J. Comput. Chem. 38, 1342–1352 (2017).
Google Scholar
Noyori, O. et al. Suppression of Fas-mediated apoptosis via steric shielding by filovirus glycoproteins. Biochem. Biophys. Res. Commun. 441, 994–998 (2013).
Google Scholar
Noyori, O. et al. Differential potential for envelope glycoprotein-mediated steric shielding of host cell surface proteins among filoviruses. Virology 446, 152–161 (2013).
Google Scholar
Cao, Z. et al. Ebola virus VP35 perturbs type I interferon signaling to facilitate viral replication. Virol. Sin. 38, 922–930 (2023).
Google Scholar
Martines, R. B. et al. Tissue and cellular tropism, pathology and pathogenesis of Ebola and Marburg viruses. J. Pathol. 235, 153–174 (2015).
Google Scholar
Sanchez, A. et al. Biochemical analysis of the secreted and virion glycoproteins of Ebola virus. J. Virol. 72, 6442–6447 (1998).
Google Scholar
Ito, H., Watanabe, S., Takada, A. & Kawaoka, Y. Ebola virus glycoprotein: proteolytic processing, acylation, cell tropism, and detection of neutralizing antibodies. J. Virol. 75, 1576–1580, (2001).
Google Scholar
Kindzelskii, A. L. et al. Ebola virus secretory glycoprotein (sGP) diminishes Fc gamma RIIIB-to-CR3 proximity on neutrophils. J. Immunol. 164, 953–958 (2000).
Google Scholar
Wahl-Jensen, V. M. et al. Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function. J. Virol. 79, 10442–10450 (2005).
Google Scholar
Suzuki, Y. & Gojobori, T. The origin and evolution of Ebola and Marburg viruses. Mol. Biol. Evol. 14, 800–806, (1997).
Google Scholar
Barrette, R. W. et al. Discovery of swine as a host for the Reston ebolavirus. Science 325, 204–206 (2009).
Google Scholar
Pan, Y. et al. Reston virus in domestic pigs in China. Arch. Virol. 159, 1129–1132 (2014).
Google Scholar
Swanepoel, R. et al. Studies of reservoir hosts for Marburg virus. Emerg. Infect. Dis. 13, 1847–1851 (2007).
Google Scholar
Towner, J. S. et al. Isolation of genetically diverse Marburg viruses from Egyptian fruit bats. PLoS Pathog. 5, e1000536 (2009).
Google Scholar
Gowen, B. B. & Holbrook, M. R. Animal models of highly pathogenic RNA viral infections: hemorrhagic fever viruses. Antivir. Res. 78, 79–90 (2008).
Google Scholar
Towner, J. S. et al. Marburgvirus genomics and association with a large hemorrhagic fever outbreak in Angola. J. Virol. 80, 6497–6516 (2006).
Google Scholar
Mahanty, S. & Bray, M. Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect. Dis. 4, 487–498, (2004).
Google Scholar
Robinson, J. E. et al. Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. Nat. Commun. 7, 11544 (2016).
Google Scholar
Brauburger, K., Hume, A. J., Mühlberger, E. & Olejnik, J. Forty-five years of Marburg virus research. Viruses 4, 1878–1927 (2012).
Google Scholar
Shifflett, K. & Marzi, A. Marburg virus pathogenesis – differences and similarities in humans and animal models. Virol. J. 16, 165 (2019).
Google Scholar
Geisbert, T. W. et al. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 362, 1953–1958 (2003).
Google Scholar
Warfield, K. L. et al. Development and characterization of a mouse model for Marburg hemorrhagic fever. J. Virol. 83, 6404–6415 (2009).
Google Scholar
Bray, M. The role of the Type I interferon response in the resistance of mice to filovirus infection. J. Gen. Virol. 82, 1365–1373 (2001).
Google Scholar
Hofmann, H. & Kunz, C. [A strain of “Marburg virus” (Rhabdovirus simiae) pathogenic to mice]. Arch. Gesamt. Virusforsch. 32, 244–248, (1970).
Google Scholar
Moe, J. B., Lambert, R. D. & Lupton, H. W. Plaque assay for Ebola virus. J. Clin. Microbiol 13, 791–793 (1981).
Google Scholar
Banadyga, L., Dolan, M. A. & Ebihara, H. Rodent-Adapted Filoviruses and the Molecular Basis of Pathogenesis. J. Mol. Biol. 428, 3449–3466 (2016).
Google Scholar
Bray, M. et al. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J. Infect. Dis. 179, S248–S258 (1999).
Google Scholar
Ebihara, H. et al. Molecular determinants of Ebola virus virulence in mice. PLoS Pathog. 2, e73 (2006).
Google Scholar
Ramanan, P. et al. Filoviral immune evasion mechanisms. Viruses 3, 1634–1649 (2011).
Google Scholar
Gibb, T. R. et al. Pathogenesis of experimental Ebola Zaire virus infection in BALB/c mice. J. Comp. Pathol. 125, 233–242 (2001).
Google Scholar
Geisbert, T. W. et al. Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J. Infect. Dis. 188, 1618–1629 (2003).
Google Scholar
Villinger, F. et al. Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection. J. Infect. Dis. 179, S188–S191 (1999).
Google Scholar
Baize, S. et al. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat. Med. 5, 423–426 (1999).
Google Scholar
Raymond, J., Bradfute, S. & Bray, M. Filovirus infection of STAT-1 knockout mice. J. Infect. Dis. 204, S986–S990 (2011).
Google Scholar
Lever, M. S. et al. Lethality and pathogenesis of airborne infection with filoviruses in A129 α/β −/− interferon receptor-deficient mice. J. Med. Microbiol. 61, 8–15 (2012).
Google Scholar
Escaffre, O. et al. STAT-1 Knockout Mice as a Model for Wild-Type Sudan Virus (SUDV). Viruses 13, 1388 (2021).
Google Scholar
Warfield, K. L. et al. Development of a model for marburgvirus based on severe-combined immunodeficiency mice. Virol. J. 4, 108 (2007).
Google Scholar
Qiu, X. et al. Establishment and characterization of a lethal mouse model for the Angola strain of Marburg virus. J. Virol. 88, 12703–12714 (2014).
Google Scholar
Wei, H. et al. Deep-sequencing of Marburg virus genome during sequential mouse passaging and cell-culture adaptation reveals extensive changes over time. Sci. Rep. 7, 3390 (2017).
Google Scholar
Valmas, C. & Basler, C. F. Marburg virus VP40 antagonizes interferon signaling in a species-specific manner. J. Virol. 85, 4309–4317 (2011).
Google Scholar
Bird, B. H. et al. Humanized Mouse Model of Ebola Virus Disease Mimics the Immune Responses in Human Disease. J. Infect. Dis. 213, 703–711 (2016).
Google Scholar
Escudero-Pérez, B. et al. Comparative pathogenesis of Ebola virus and Reston virus infection in humanized mice. JCI Insight 4, e126070 (2019).
Google Scholar
Rasmussen, A. L. et al. Host genetic diversity enables Ebola hemorrhagic fever pathogenesis and resistance. Science 346, 987–991 (2014).
Google Scholar
Lavender, K. J. et al. Pathogenicity of Ebola and Marburg Viruses Is Associated With Differential Activation of the Myeloid Compartment in Humanized Triple Knockout-Bone Marrow, Liver, and Thymus Mice. J. Infect. Dis. 218, S409–s417 (2018).
Google Scholar
Bradfute, S. B. et al. Lymphocyte death in a mouse model of Ebola virus infection. J. Infect. Dis. 196, S296–S304 (2007).
Google Scholar
Bradfute, S. B. et al. Mechanisms and consequences of ebolavirus-induced lymphocyte apoptosis. J. Immunol. 184, 327–335 (2010).
Google Scholar
Ebihara, H. et al. A Syrian golden hamster model recapitulating ebola hemorrhagic fever. J. Infect. Dis. 207, 306–318 (2013).
Google Scholar
Ebihara, H. et al. Host response dynamics following lethal infection of rhesus macaques with Zaire ebolavirus. J. Infect. Dis. 204, S991–S999 (2011).
Google Scholar
Atkins, C. et al. Natural History and Pathogenesis of Wild-Type Marburg Virus Infection in STAT2 Knockout Hamsters. J. Infect. Dis. 218, S438–s447 (2018).
Google Scholar
Marzi, A. et al. A hamster model for Marburg virus infection accurately recapitulates Marburg hemorrhagic fever. Sci. Rep. 6, 39214 (2016).
Google Scholar
Bowen, E. T. et al. Viral haemorrhagic fever in southern Sudan and northern Zaire. Preliminary studies on the aetiological agent. Lancet 1, 571–573 (1977).
Google Scholar
Connolly, B. M. et al. Pathogenesis of experimental Ebola virus infection in guinea pigs. J. Infect. Dis. 179, S203–S217 (1999).
Google Scholar
Ryabchikova, E. et al. Ebola virus infection in guinea pigs: presumable role of granulomatous inflammation in pathogenesis. Arch. Virol. 141, 909–921 (1996).
Google Scholar
Subbotina, E., Dadaeva, A., Kachko, A. & Chepurnov, A. Genetic factors of Ebola virus virulence in guinea pigs. Virus Res. 153, 121–133 (2010).
Google Scholar
Cross, R. W. et al. Modeling the Disease Course of Zaire ebolavirus Infection in the Outbred Guinea Pig. J. Infect. Dis. 212, S305–S315 (2015).
Google Scholar
Wong, G. et al. Development and Characterization of a Guinea Pig-Adapted Sudan Virus. J. Virol. 90, 392–399 (2016).
Google Scholar
Simpson, D. I., Zlotnik, I. & Rutter, D. A. Vervet monkey disease. Experiment infection of guinea pigs and monkeys with the causative agent. Br. J. Exp. Pathol. 49, 458–464 (1968).
Google Scholar
Cross, R. W. et al. Comparison of the Pathogenesis of the Angola and Ravn Strains of Marburg Virus in the Outbred Guinea Pig Model. J. Infect. Dis. 212, S258–S270 (2015).
Google Scholar
Hevey, M. et al. Antigenicity and vaccine potential of Marburg virus glycoprotein expressed by baculovirus recombinants. Virology 239, 206–216 (1997).
Google Scholar
Fenollar, F. et al. Mink, SARS-CoV-2, and the Human-Animal Interface. Front. Microbiol. 12, 663815 (2021).
Google Scholar
Cross, R. W. et al. The Domestic Ferret (Mustela putorius furo) as a Lethal Infection Model for 3 Species of Ebolavirus. J. Infect. Dis. 214, 565–569 (2016).
Google Scholar
Wong, G. et al. The Makona Variant of Ebola Virus Is Highly Lethal to Immunocompromised Mice and Immunocompetent Ferrets. J. Infect. Dis. 218, S466–S470 (2018).
Google Scholar
Kozak, R. et al. Ferrets Infected with Bundibugyo Virus or Ebola Virus Recapitulate Important Aspects of Human Filovirus Disease. J. Virol. 90, 9209–9223 (2016).
Google Scholar
Brasel, T. et al. Mucosal Challenge Ferret Models of Ebola Virus Disease. Pathogens 10, 292 (2021).
Google Scholar
Kroeker, A. et al. Characterization of Sudan Ebolavirus infection in ferrets. Oncotarget 8, 46262–46272 (2017).
Google Scholar
Burk, R. et al. Neglected filoviruses. FEMS Microbiol. Rev. 40, 494–519 (2016).
Google Scholar
Geisbert, T. W. & Jahrling, P. B. Use of immunoelectron microscopy to show Ebola virus during the 1989 United States epizootic. J. Clin. Pathol. 43, 813–816 (1990).
Google Scholar
Yan, F. et al. Characterization of Reston virus infection in ferrets. Antivir. Res. 165, 1–10 (2019).
Google Scholar
Schiffman, Z. et al. Taï Forest Virus Does Not Cause Lethal Disease in Ferrets. Microorganisms 9, 213 (2021).
Google Scholar
Cross, R. W. et al. Marburg and Ravn Viruses Fail to Cause Disease in the Domestic Ferret (Mustela putorius furo). J. Infect. Dis. 218, S448–S452 (2018).
Google Scholar
Wong, G. et al. Marburg and Ravn Virus Infections Do Not Cause Observable Disease in Ferrets. J. Infect. Dis. 218, S471–S474 (2018).
Google Scholar
Liu, D. X. et al. Ebola Virus Disease Features Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome in the Rhesus Macaque Model. J. Infect. Dis. 228, 371–382 (2023).
Google Scholar
Warren, T. et al. Characterization of Ebola Virus Disease (EVD) in Rhesus Monkeys for Development of EVD Therapeutics. Viruses 12, 92 (2020).
Google Scholar
Worwa, G. et al. Persistent intraocular Ebola virus RNA is associated with severe uveitis in a convalescent rhesus monkey. Commun. Biol. 5, 1204 (2022).
Google Scholar
Geisbert, T. W. et al. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab. Invest. 80, 171–186 (2000).
Google Scholar
Fisher-Hoch, S. P. et al. Haematological and biochemical monitoring of Ebola infection in rhesus monkeys: implications for patient management. Lancet 2, 1055–1058 (1983).
Google Scholar
Kortepeter, M. G. et al. Real-time monitoring of cardiovascular function in rhesus macaques infected with Zaire ebolavirus. J. Infect. Dis. 204, S1000–S1010 (2011).
Google Scholar
Baskerville, A., Fisher-Hoch, S. P., Neild, G. H. & Dowsett, A. B. Ultrastructural pathology of experimental Ebola haemorrhagic fever virus infection. J. Pathol. 147, 199–209 (1985).
Google Scholar
Hensley, L. E., Young, H. A., Jahrling, P. B. & Geisbert, T. W. Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. Immunol. Lett. 80, 169–179 (2002).
Google Scholar
Bennett, R. S. et al. Nonhuman Primate Models of Ebola Virus Disease. Curr. Top. Microbiol. Immunol. 411, 171–193 (2017).
Google Scholar
Woolsey, C. et al. Natural history of infection in rhesus and cynomolgus macaques. Emerg. Microbes Infect. 11, 1635–1646 (2022).
Google Scholar
Zumbrun, E. E. et al. A characterization of aerosolized Sudan virus infection in African green monkeys, cynomolgus macaques, and rhesus macaques. Viruses 4, 2115–2136 (2012).
Google Scholar
Gilchuk, P. et al. Efficacy of Human Monoclonal Antibody Monotherapy Against Bundibugyo Virus Infection in Nonhuman Primates. J. Infect. Dis. 218, S565–S573 (2018).
Google Scholar
Woolsey, C. et al. Bundibugyo ebolavirus Survival Is Associated with Early Activation of Adaptive Immunity and Reduced Myeloid-Derived Suppressor Cell Signaling. mBio 12, e0151721 (2021).
Google Scholar
Nicholas, V. V. et al. Distinct Biological Phenotypes of Marburg and Ravn Virus Infection in Macaques. J. Infect. Dis. 218, S458–S465 (2018).
Google Scholar
Lin, K. L. et al. Temporal Characterization of Marburg Virus Angola Infection following Aerosol Challenge in Rhesus Macaques. J. Virol. 89, 9875–9885 (2015).
Google Scholar
Hensley, L. E. et al. Pathogenesis of Marburg hemorrhagic fever in cynomolgus macaques. J. Infect. Dis. 204, S1021–S1031 (2011).
Google Scholar
Glaze, E. R., Roy, M. J., Dalrymple, L. W. & Lanning, L. L. A Comparison of the Pathogenesis of Marburg Virus Disease in Humans and Nonhuman Primates and Evaluation of the Suitability of These Animal Models for Predicting Clinical Efficacy under the ‘Animal Rule’. Comp. Med. 65, 241–259 (2015).
Google Scholar
Speranza, E. et al. A conserved transcriptional response to intranasal Ebola virus exposure in nonhuman primates prior to onset of fever. Sci. Transl. Med. 10, eaaq1016 (2018).
Google Scholar
Jankeel, A. et al. Early Transcriptional Changes within Liver, Adrenal Gland, and Lymphoid Tissues Significantly Contribute to Ebola Virus Pathogenesis in Cynomolgus Macaques. J. Virol. 94, e00250–20 (2020).
Google Scholar
Pinski, A. N., Maroney, K. J., Marzi, A. & Messaoudi, I. Distinct transcriptional responses to fatal Ebola virus infection in cynomolgus and rhesus macaques suggest species-specific immune responses. Emerg. Microbes Infect. 10, 1320–1330 (2021).
Google Scholar
Stefan, C. P. et al. Transcriptomic Analysis Reveals Host miRNAs Correlated with Immune Gene Dysregulation during Fatal Disease Progression in the Ebola Virus Cynomolgus Macaque Disease Model. Microorganisms 9, 665 (2021).
Google Scholar
Alfson, K. J. et al. Development of a Lethal Intranasal Exposure Model of Ebola Virus in the Cynomolgus Macaque. Viruses 9, 319 (2017).
Google Scholar
Johnston, S. C. et al. Delayed Disease in Cynomolgus Macaques Exposed to Ebola Virus by an Intranasal Route. Front. Immunol. 12, 709772 (2021).
Google Scholar
Sullivan, N. J. et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 424, 681–684 (2003).
Google Scholar
Reed, D. S. et al. Aerosol exposure to Zaire ebolavirus in three nonhuman primate species: differences in disease course and clinical pathology. Microbes Infect. 13, 930–936 (2011).
Google Scholar
Mire, C. E. et al. Oral and Conjunctival Exposure of Nonhuman Primates to Low Doses of Ebola Makona Virus. J. Infect. Dis. 214, S263–S267 (2016).
Google Scholar
Johnson, D. M. et al. Characterization of Ebola Virus Mucosal Challenge Routes in Cynomolgus Macaques. J. Virol. 97, e0188822 (2023).
Google Scholar
Marzi, A. et al. Delayed Disease Progression in Cynomolgus Macaques Infected with Ebola Virus Makona Strain. Emerg. Infect. Dis. 21, 1777–1783 (2015).
Google Scholar
Wong, G. et al. Pathogenicity Comparison Between the Kikwit and Makona Ebola Virus Variants in Rhesus Macaques. J. Infect. Dis. 214, S281–S289 (2016).
Google Scholar
Alfson, K. J. et al. Development of a Well-Characterized Cynomolgus Macaque Model of Sudan Virus Disease for Support of Product Development. Vaccines 10, 1723 (2022).
Google Scholar
Geisbert, T. W., Strong, J. E. & Feldmann, H. Considerations in the Use of Nonhuman Primate Models of Ebola Virus and Marburg Virus Infection. J. Infect. Dis. 212, S91–S97 (2015).
Google Scholar
McElroy, A. K. et al. Ebola hemorrhagic Fever: novel biomarker correlates of clinical outcome. J. Infect. Dis. 210, 558–566 (2014).
Google Scholar
Wauquier, N. et al. Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis. PLoS Negl. Trop. Dis. 4, e837 (2010).
Google Scholar
Henn, V. et al. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 98, 1047–1054 (2001).
Google Scholar
Alfson, K. J. et al. Intramuscular Exposure of to Low Doses of Low Passage- or Cell Culture-Adapted Sudan Virus or Ebola Virus. Viruses 10, 642 (2018).
Google Scholar
Trefry, J. C. et al. Ebola Virus Infections in Nonhuman Primates Are Temporally Influenced by Glycoprotein Poly-U Editing Site Populations in the Exposure Material. Viruses 7, 6739–6754 (2015).
Google Scholar
Alfson, K. J. et al. Development of a Well-Characterized Cynomolgus Macaque Model of Marburg Virus Disease for Support of Vaccine and Therapy Development. Vaccines 10, 1314 (2022).
Google Scholar
Hensley, L. E. et al. Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species. PLoS Pathog. 6, e1000904 (2010).
Google Scholar
Jahrling, P. B. et al. Experimental infection of cynomolgus macaques with Ebola-Reston filoviruses from the 1989-1990 U.S. epizootic. Arch. Virol. Suppl. 11, 115–134 (1996).
Google Scholar
Taniguchi, S. et al. Analysis of the humoral immune responses among cynomolgus macaque naturally infected with Reston virus during the 1996 outbreak in the Philippines. BMC Vet. Res. 8, 189 (2012).
Google Scholar
Hutchinson, K. L. et al. Multiplex analysis of cytokines in the blood of cynomolgus macaques naturally infected with Ebola virus (Reston serotype). J. Med. Virol. 65, 561–566 (2001).
Google Scholar
Ikegami, T. et al. Histopathology of natural Ebola virus subtype Reston infection in cynomolgus macaques during the Philippine outbreak in 1996. Exp. Anim. 51, 447–455 (2002).
Google Scholar
Geisbert, T. W. et al. Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J. Virol. 83, 7296–7304 (2009).
Google Scholar
Comer, J. E. et al. Natural History of Marburg Virus Infection to Support Medical Countermeasure Development. Viruses 14, 2291 (2022).
Google Scholar
Ryabchikova, E. I., Kolesnikova, L. V. & Luchko, S. V. An analysis of features of pathogenesis in two animal models of Ebola virus infection. J. Infect. Dis. 179, S199–S202 (1999).
Google Scholar
Carrion, R. et al. A small nonhuman primate model for filovirus-induced disease. Virology 420, 117–124 (2011).
Google Scholar
Smither, S. J. et al. Experimental Respiratory Infection of Marmosets (Callithrix jacchus) With Ebola Virus Kikwit. J. Infect. Dis. 212, S336–S345 (2015).
Google Scholar
Perry, D. L., Bollinger, L. & White, G. L. The Baboon (Papio spp.) as a model of human Ebola virus infection. Viruses 4, 2400–2416 (2012).
Google Scholar
Ignatiev, G. M., Dadaeva, A. A., Luchko, S. V. & Chepurnov, A. A. Immune and pathophysiological processes in baboons experimentally infected with Ebola virus adapted to guinea pigs. Immunol. Lett. 71, 131–140 (2000).
Google Scholar
McWilliams, I. L. et al. Pseudovirus rVSVΔG-ZEBOV-GP Infects Neurons in Retina and CNS, Causing Apoptosis and Neurodegeneration in Neonatal Mice. Cell Rep. 26, 1718–1726.e4 (2019).
Google Scholar
Yang, W. et al. Establishment and application of a surrogate model for human Ebola virus disease in BSL-2 laboratory. Virol. Sin. 39, 434–446 (2024).
Google Scholar
Lee, H.-N. et al. Characterization of the therapeutic effect of antibodies targeting the Ebola glycoprotein using a novel BSL2-compliant rVSVΔG-EBOV-GP infection model. Emerg. Microbes Infect. 10, 2076–2089 (2021).
Google Scholar
Saito, T. et al. A Surrogate Animal Model for Screening of Ebola and Marburg Glycoprotein-Targeting Drugs Using Pseudotyped Vesicular Stomatitis Viruses. Viruses 12, 923 (2020).
Google Scholar
Jones, S. M. et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med. 11, 786–790 (2005).
Google Scholar
Qiu, X. et al. Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses. PLoS One 4, e5547 (2009).
Google Scholar
Menicucci, A. R. et al. Antiviral Innate Responses Induced by VSV-EBOV Vaccination Contribute to Rapid Protection. mBio 10, e00597–00519 (2019).
Google Scholar
Huttner, A. et al. Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study. Lancet Infect. Dis. 18, 738–748 (2018).
Google Scholar
Agnandji, S. T. et al. Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe. N. Engl. J. Med. 374, 1647–1660, (2016).
Google Scholar
Regules, J. A. et al. A Recombinant Vesicular Stomatitis Virus Ebola Vaccine. N. Engl. J. Med. 376, 330–341 (2017).
Google Scholar
Henao-Restrepo, A. M. et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!). Lancet 389, 505–518 (2017).
Google Scholar
Callaway, E. Make Ebola a thing of the past’: first vaccine against deadly virus approved. Nature 575, 425–426 (2019).
Google Scholar
Wu, S. et al. An Adenovirus Vaccine Expressing Ebola Virus Variant Makona Glycoprotein Is Efficacious in Guinea Pigs and Nonhuman Primates. J. Infect. Dis. 214, S326–S332 (2016).
Google Scholar
Zhu, F. C. et al. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet 385, 2272–2279 (2015).
Google Scholar
Lihua, W. et al. Open-label phase I clinical trial of Ad5-EBOV in Africans in China. Hum. Vaccin Immunother. 13, 2078–2085 (2017).
Google Scholar
Li, J. X. et al. Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Glob. Health 5, e324–e334 (2017).
Google Scholar
Zhu, F.-C. et al. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 389, 621–628 (2017).
Google Scholar
Stanley, D. A. et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat. Med. 20, 1126–1129 (2014).
Google Scholar
Ledgerwood, J. E. et al. Chimpanzee Adenovirus Vector Ebola Vaccine. N. Engl. J. Med. 376, 928–938 (2017).
Google Scholar
Ewer, K. et al. A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. N. Engl. J. Med. 374, 1635–1646, (2016).
Google Scholar
Tapia, M. D. et al. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infect. Dis. 16, 31–42 (2016).
Google Scholar
Dolzhikova, I. V. et al. Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia. Hum. Vaccin Immunother. 13, 613–620 (2017).
Google Scholar
Sullivan, N. J. et al. Development of a preventive vaccine for Ebola virus infection in primates. Nature 408, 605–609 (2000).
Google Scholar
Kennedy, S. B. et al. Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia. N. Engl. J. Med. 377, 1438–1447 (2017).
Google Scholar
Agua-Agum, J. et al. Ebola virus disease among children in West Africa. N. Engl. J. Med. 372, 1274–1277 (2015).
Google Scholar
Sullivan, N. J. et al. CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat. Med. 17, 1128–1131 (2011).
Google Scholar
Reynolds, P. & Marzi, A. Ebola and Marburg virus vaccines. Virus Genes 53, 501–515 (2017).
Google Scholar
Martin, J. E. et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin. Vaccin. Immunol. 13, 1267–1277 (2006).
Google Scholar
Falzarano, D., Geisbert, T. W. & Feldmann, H. Progress in filovirus vaccine development: evaluating the potential for clinical use. Expert Rev. Vaccines 10, 63–77 (2011).
Google Scholar
Geisbert, T. W. et al. Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates. J. Virol. 84, 10386–10394 (2010).
Google Scholar
Marzi, A. et al. Vesicular stomatitis virus-based vaccines against Lassa and Ebola viruses. Emerg. Infect. Dis. 21, 305–307 (2015).
Google Scholar
Cross, R. W. et al. Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death. J. Clin. Invest 130, 539–551 (2019).
Google Scholar
Furuyama, W. & Marzi, A. Ebola Virus: Pathogenesis and Countermeasure Development. Annu. Rev. Virol. 6, 435–458 (2019).
Google Scholar
Wong, G. et al. Ebola-specific therapeutic antibodies from lab to clinic: The example of ZMapp. Antivir. Res. 226, 105873 (2024).
Google Scholar
Nakkazi, E. Randomised controlled trial begins for Ebola therapeutics. Lancet 392, 2338 (2018).
Google Scholar
Qiu, X. et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514, 47–53 (2014).
Google Scholar
Pascal, K. E. et al. Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates. J. Infect. Dis. 218, S612–S626 (2018).
Google Scholar
Lyon, G. M. et al. Clinical care of two patients with Ebola virus disease in the United States. N. Engl. J. Med. 371, 2402–2409 (2014).
Google Scholar
Fausther-Bovendo, H. & Kobinger, G. The road to effective and accessible antibody therapies against Ebola virus. Curr. Opin. Virol. 54, 101210 (2022).
Google Scholar
Rayaprolu, V. et al. Structure of the Inmazeb cocktail and resistance to Ebola virus escape. Cell Host Microbe 31, 260–272.e7 (2023).
Google Scholar
Levine, M. M. Monoclonal Antibody Therapy for Ebola Virus Disease. N. Engl. J. Med. 381, 2365–2366 (2019).
Google Scholar
Gaudinski, M. R. et al. Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study. Lancet 393, 889–898 (2019).
Google Scholar
Markham, A. REGN-EB3: First Approval. Drugs 81, 175–178 (2021).
Google Scholar
Mulangu, S. et al. A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. N. Engl. J. Med. 381, 2293–2303 (2019).
Google Scholar
Mullard, A. FDA approves antibody cocktail for Ebola virus. Nat. Rev. Drug Discov. 19, 827 (2020).
Google Scholar
Flyak, A. I. et al. Mechanism of human antibody-mediated neutralization of Marburg virus. Cell 160, 893–903 (2015).
Google Scholar
Mire, C. E. et al. Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody. Sci. Transl. Med. 9, eaai8711 (2017).
Google Scholar
Cross, R. W., Mire, C. E., Feldmann, H. & Geisbert, T. W. Post-exposure treatments for Ebola and Marburg virus infections. Nat. Rev. Drug Discov. 17, 413–434 (2018).
Google Scholar
Sissoko, D. et al. Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. PLoS Med. 13, e1001967 (2016).
Google Scholar
Bixler, S. L. et al. Efficacy of favipiravir (T-705) in nonhuman primates infected with Ebola virus or Marburg virus. Antivir. Res. 151, 97–104 (2018).
Google Scholar
Jacobs, M. et al. Late Ebola virus relapse causing meningoencephalitis: a case report. Lancet 388, 498–503 (2016).
Google Scholar
Dörnemann, J. et al. First Newborn Baby to Receive Experimental Therapies Survives Ebola Virus Disease. J. Infect. Dis. 215, 171–174 (2017).
Google Scholar
Porter, D. P. et al. Remdesivir (GS-5734) Is Efficacious in Cynomolgus Macaques Infected With Marburg Virus. J. Infect. Dis. 222, 1894–1901 (2020).
Google Scholar
Iversen, P. L. et al. Discovery and early development of AVI-7537 and AVI-7288 for the treatment of Ebola virus and Marburg virus infections. Viruses 4, 2806–2830 (2012).
Google Scholar
Heald, A. E. et al. AVI-7288 for Marburg Virus in Nonhuman Primates and Humans. N. Engl. J. Med. 373, 339–348 (2015).
Google Scholar
Heald, A. E. et al. Safety and pharmacokinetic profiles of phosphorodiamidate morpholino oligomers with activity against ebola virus and marburg virus: results of two single-ascending-dose studies. Antimicrob. Agents Chemother. 58, 6639–6647 (2014).
Google Scholar
Ursic-Bedoya, R. et al. Protection against lethal Marburg virus infection mediated by lipid encapsulated small interfering RNA. J. Infect. Dis. 209, 562–570 (2014).
Google Scholar
Thi, E. P. et al. Marburg virus infection in nonhuman primates: Therapeutic treatment by lipid-encapsulated siRNA. Sci. Transl. Med. 6, 250ra116 (2014).
Google Scholar
Monath, T. P. et al. Lassa virus isolation from Mastomys natalensis rodents during an epidemic in Sierra Leone. Science 185, 263–265 (1974).
Google Scholar
Oldstone, M. B. Arenaviruses. I. The epidemiology molecular and cell biology of arenaviruses. Introduction. Curr. Top. Microbiol Immunol. 262, V–xii (2002).
Google Scholar
Hastie, K. M. et al. Structure of the Lassa virus nucleoprotein reveals a dsRNA-specific 3’ to 5’ exonuclease activity essential for immune suppression. Proc. Natl Acad. Sci. USA 108, 2396–2401 (2011).
Google Scholar
Hastie, K. M. et al. Crystal structure of the Lassa virus nucleoprotein-RNA complex reveals a gating mechanism for RNA binding. Proc. Natl Acad. Sci. USA 108, 19365–19370 (2011).
Google Scholar
Katz, M. et al. Structure and receptor recognition by the Lassa virus spike complex. Nature 603, 174–179 (2022).
Google Scholar
Li, S. et al. Acidic pH-Induced Conformations and LAMP1 Binding of the Lassa Virus Glycoprotein Spike. PLoS Pathog. 12, e1005418 (2016).
Google Scholar
Israeli, H. et al. Mapping of the Lassa virus LAMP1 binding site reveals unique determinants not shared by other old world arenaviruses. PLoS Pathog. 13, e1006337 (2017).
Google Scholar
Kouba, T. et al. Conformational changes in Lassa virus L protein associated with promoter binding and RNA synthesis activity. Nat. Commun. 12, 7018 (2021).
Google Scholar
Hastie, K. M. et al. Crystal Structure of the Oligomeric Form of Lassa Virus Matrix Protein Z. J. Virol. 90, 4556–4562 (2016).
Google Scholar
Andersen, K. G. et al. Clinical Sequencing Uncovers Origins and Evolution of Lassa Virus. Cell 162, 738–750 (2015).
Google Scholar
Pinneo, L. & Pinneo, R. Mystery virus from Lassa. Am. J. Nurs. 71, 1352–1355, (1971).
Google Scholar
Ehichioya, D. U. et al. Phylogeography of Lassa Virus in Nigeria. J Virol. 93, e00929-19 (2019).
Bowen, M. D. et al. Genetic diversity among Lassa virus strains. J. Virol. 74, 6992–7004 (2000).
Google Scholar
Whitmer, S. L. M. et al. New Lineage of Lassa Virus, Togo, 2016. Emerg. Infect. Dis. 24, 599–602 (2018).
Google Scholar
Macher, A. M. & Wolfe, M. S. Historical Lassa fever reports and 30-year clinical update. Emerg. Infect. Dis. 12, 835–837, (2006).
Google Scholar
Ehlkes, L. et al. Management of a Lassa fever outbreak, Rhineland-Palatinate, Germany, 2016. Eur. Surveill. 22, 16–00728 (2017).
Google Scholar
Njuguna, C. et al. A challenging response to a Lassa fever outbreak in a non endemic area of Sierra Leone in 2019 with export of cases to The Netherlands. Int. J. Infect. Dis. 117, 295–301 (2022).
Google Scholar
Brosh-Nissimov, T. Lassa fever: another threat from West Africa. Disaster Mil. Med. 2, 8 (2016).
Google Scholar
Hastie, K. M., Bale, S., Kimberlin, C. R. & Saphire, E. O. Hiding the evidence: two strategies for innate immune evasion by hemorrhagic fever viruses. Curr. Opin. Virol. 2, 151–156, (2012).
Google Scholar
Günther, S. et al. Lassa fever encephalopathy: Lassa virus in cerebrospinal fluid but not in serum. J. Infect. Dis. 184, 345–349 (2001).
Google Scholar
Mahanty, S. et al. Low levels of interleukin-8 and interferon-inducible protein-10 in serum are associated with fatal infections in acute Lassa fever. J. Infect. Dis. 183, 1713–1721 (2001).
Google Scholar
Mahanty, S. et al. Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J. Immunol. 170, 2797–2801 (2003).
Google Scholar
Baize, S. et al. Lassa virus infection of human dendritic cells and macrophages is productive but fails to activate cells. J. Immunol. 172, 2861–2869 (2004).
Google Scholar
Pannetier, D. et al. Human dendritic cells infected with the nonpathogenic Mopeia virus induce stronger T-cell responses than those infected with Lassa virus. J. Virol. 85, 8293–8306 (2011).
Google Scholar
Walker, D. H., Wulff, H., Lange, J. V. & Murphy, F. A. Comparative pathology of Lassa virus infection in monkeys, guinea-pigs, and Mastomys natalensis. Bull. World Health Organ. 52, 523–534 (1975).
Google Scholar
Uckun, F. M. et al. Stampidine prevents mortality in an experimental mouse model of viral hemorrhagic fever caused by lassa virus. BMC Infect. Dis. 4, 1 (2004).
Google Scholar
Rieger, T., Merkler, D. & Günther, S. Infection of type I interferon receptor-deficient mice with various old world arenaviruses: a model for studying virulence and host species barriers. PLoS One 8, e72290 (2013).
Google Scholar
Yun, N. E. et al. Mice lacking functional STAT1 are highly susceptible to lethal infection with Lassa virus. J. Virol. 87, 10908–10911 (2013).
Google Scholar
Oestereich, L. et al. Chimeric Mice with Competent Hematopoietic Immunity Reproduce Key Features of Severe Lassa Fever. PLoS Pathog. 12, e1005656 (2016).
Google Scholar
Yun, N. E. et al. Functional interferon system is required for clearance of lassa virus. J. Virol. 86, 3389–3392 (2012).
Google Scholar
Oestereich, L. et al. Efficacy of Favipiravir Alone and in Combination With Ribavirin in a Lethal, Immunocompetent Mouse Model of Lassa Fever. J. Infect. Dis. 213, 934–938 (2016).
Google Scholar
Yun, N. E. et al. Animal Model of Sensorineural Hearing Loss Associated with Lassa Virus Infection. J. Virol. 90, 2920–2927 (2015).
Google Scholar
Flatz, L. et al. T cell-dependence of Lassa fever pathogenesis. PLoS Pathog. 6, e1000836 (2010).
Google Scholar
Buchmeier, M. J. & Rawls, W. E. Variation between strains of hamsters in the lethality of Pichinde virus infections. Infect. Immun. 16, 413–421 (1977).
Google Scholar
Xiao, S. Y., Zhang, H., Yang, Y. & Tesh, R. B. Pirital virus (Arenaviridae) infection in the syrian golden hamster, Mesocricetus auratus: a new animal model for arenaviral hemorrhagic fever. Am. J. Trop. Med. Hyg. 64, 111–118 (2001).
Google Scholar
Lukashevich, I. S. The search for animal models for Lassa fever vaccine development. Expert Rev. Vaccines 12, 71–86 (2013).
Google Scholar
Cashman, K. A. et al. Evaluation of Lassa antiviral compound ST-193 in a guinea pig model. Antivir. Res. 90, 70–79 (2011).
Google Scholar
Gary, J. M. et al. Lassa Virus Targeting of Anterior Uvea and Endothelium of Cornea and Conjunctiva in Eye of Guinea Pig Model. Emerg. Infect. Dis. 25, 865–874 (2019).
Google Scholar
Stein, D. R. et al. A recombinant vesicular stomatitis-based Lassa fever vaccine elicits rapid and long-term protection from lethal Lassa virus infection in guinea pigs. NPJ Vaccines 4, 8 (2019).
Google Scholar
Stein, D. R. et al. Differential pathogenesis of closely related 2018 Nigerian outbreak clade III Lassa virus isolates. PLoS Pathog. 17, e1009966 (2021).
Google Scholar
Liu, D. X. et al. Persistence of Lassa Virus Associated With Severe Systemic Arteritis in Convalescing Guinea Pigs (Cavia porcellus). J. Infect. Dis. 219, 1818–1822 (2019).
Google Scholar
Huynh, T. et al. Lassa virus antigen distribution and inflammation in the ear of infected strain 13/N Guinea pigs. Antivir. Res. 183, 104928 (2020).
Google Scholar
Jahrling, P. B., Smith, S., Hesse, R. A. & Rhoderick, J. B. Pathogenesis of Lassa virus infection in guinea pigs. Infect. Immun. 37, 771–778, (1982).
Google Scholar
Sattler, R. A., Paessler, S., Ly, H. & Huang, C. Animal Models of Lassa Fever. Pathogens 9, 197 (2020).
Google Scholar
Safronetz, D. et al. The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset. Sci. Rep. 5, 14775 (2015).
Google Scholar
Maruyama, J. et al. Lethal Infection of Lassa Virus Isolated from a Human Clinical Sample in Outbred Guinea Pigs without Adaptation. mSphere 4, e00428–00419 (2019).
Google Scholar
Warner, B. M., Safronetz, D. & Stein, D. R. Current research for a vaccine against Lassa hemorrhagic fever virus. Drug Des. Devel Ther. 12, 2519–2527 (2018).
Google Scholar
Warner, B. M., Siragam, V. & Stein, D. R. Assessment of antiviral therapeutics in animal models of Lassa fever. Curr. Opin. Virol. 37, 84–90 (2019).
Google Scholar
Walker, D. H. et al. Experimental infection of rhesus monkeys with Lassa virus and a closely related arenavirus, Mozambique virus. J. Infect. Dis. 146, 360–368 (1982).
Google Scholar
Fisher-Hoch, S. P. et al. Physiological and immunologic disturbances associated with shock in a primate model of Lassa fever. J. Infect. Dis. 155, 465–474 (1987).
Google Scholar
Yun, N. E. & Walker, D. H. Pathogenesis of Lassa fever. Viruses 4, 2031–2048 (2012).
Google Scholar
Baillet, N. et al. Systemic viral spreading and defective host responses are associated with fatal Lassa fever in macaques. Commun. Biol. 4, 27 (2021).
Google Scholar
Hensley, L. E. et al. Pathogenesis of Lassa fever in cynomolgus macaques. Virol. J. 8, 205 (2011).
Google Scholar
Mateo, M. et al. Pathogenesis of recent Lassa virus isolates from lineages II and VII in cynomolgus monkeys. Virulence 13, 654–669 (2022).
Google Scholar
Safronetz, D. et al. A recently isolated Lassa virus from Mali demonstrates atypical clinical disease manifestations and decreased virulence in cynomolgus macaques. J. Infect. Dis. 207, 1316–1327 (2013).
Google Scholar
Downs, I. L. et al. Natural History of Aerosol Induced Lassa Fever in Non‑Human Primates. Viruses 12, 593 (2020).
Google Scholar
Baize, S. et al. Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys. J. Virol. 83, 5890–5903 (2009).
Google Scholar
Carrion, R. Jr. et al. Lassa virus infection in experimentally infected marmosets: liver pathology and immunophenotypic alterations in target tissues. J. Virol. 81, 6482–6490 (2007).
Google Scholar
Trapido, H. & Sanmartín, C. Pichindé virus, a new virus of the Tacaribe group from Colombia. Am. J. Trop. Med. Hyg. 20, 631–641 (1971).
Google Scholar
Walker, D. H., Wulff, H. & Murphy, F. A. Experimental Lassa virus infection in the squirrel monkey. Am. J. Pathol. 80, 261–278 (1975).
Google Scholar
Jahrling, P. B. et al. Pathogenesis of a pichinde virus strain adapted to produce lethal infections in guinea pigs. Infect. Immun. 32, 872–880 (1981).
Google Scholar
Connolly, B. M. et al. Pathogenesis of Pichinde virus infection in strain 13 guinea pigs: an immunocytochemical, virologic, and clinical chemistry study. Am. J. Trop. Med. Hyg. 49, 10–24 (1993).
Google Scholar
Cosgriff, T. M. et al. Studies of the coagulation system in arenaviral hemorrhagic fever: experimental infection of strain 13 guinea pigs with Pichinde virus. Am. J. Trop. Med. Hyg. 36, 416–423 (1987).
Google Scholar
Zhang, L., Marriott, K. A., Harnish, D. G. & Aronson, J. F. Reassortant analysis of guinea pig virulence of pichinde virus variants. Virology 290, 30–38 (2001).
Google Scholar
Lan, S. et al. Development of infectious clones for virulent and avirulent pichinde viruses: a model virus to study arenavirus-induced hemorrhagic fevers. J. Virol. 83, 6357–6362 (2009).
Google Scholar
Campo, A. et al. Impairment in auditory and visual function follows perinatal viral infection in the rat. Int. J. Neurosci. 27, 85–90 (1985).
Google Scholar
Lukashevich, I. S. et al. Arenavirus-mediated liver pathology: acute lymphocytic choriomeningitis virus infection of rhesus macaques is characterized by high-level interleukin-6 expression and hepatocyte proliferation. J. Virol. 77, 1727–1737 (2003).
Google Scholar
Uwishema, O. et al. Lassa fever amidst the COVID-19 pandemic in Africa: A rising concern, efforts, challenges, and future recommendations. J. Med. Virol. 93, 6433–6436 (2021).
Google Scholar
Abreu-Mota, T. et al. Non-neutralizing antibodies elicited by recombinant Lassa–Rabies vaccine are critical for protection against Lassa fever. Nat. Commun. 9, 4223 (2018).
Google Scholar
Galan-Navarro, C. et al. Oxidation-sensitive polymersomes as vaccine nanocarriers enhance humoral responses against Lassa virus envelope glycoprotein. Virology 512, 161–171 (2017).
Google Scholar
Cai, Y. et al. A Lassa Virus Live-Attenuated Vaccine Candidate Based on Rearrangement of the Intergenic Region. mBio 11, e00186–20 (2020).
Google Scholar
Cai, Y. et al. A Lassa Fever Live-Attenuated Vaccine Based on Codon Deoptimization of the Viral Glycoprotein Gene. mBio 11, e00039–20 (2020).
Google Scholar
Wulff, H., McIntosh, B. M., Hamner, D. B. & Johnson, K. M. Isolation of an arenavirus closely related to Lassa virus from Mastomys natalensis in south-east Africa. B World Health Organ. 55, 441–444 (1977).
Google Scholar
Salami, K. et al. A review of Lassa fever vaccine candidates. Curr. Opin. Virol. 37, 105–111 (2019).
Google Scholar
Zapata, J. C. et al. Genetic variation in vitro and in vivo of an attenuated Lassa vaccine candidate. J. Virol. 88, 3058–3066 (2014).
Google Scholar
Carrion, R. et al. A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity. Vaccine 25, 4093–4102 (2007).
Google Scholar
Lukashevich, I. S. et al. Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates. Vaccine 26, 5246–5254 (2008).
Google Scholar
Carnec, X. et al. A Vaccine Platform against Arenaviruses Based on a Recombinant Hyperattenuated Mopeia Virus Expressing Heterologous Glycoproteins. J. Virol. 92, e02230–17 (2018).
Google Scholar
Geisbert, T. W. et al. Development of a new vaccine for the prevention of Lassa fever. PLoS Med. 2, e183 (2005).
Google Scholar
Safronetz, D. et al. A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses. PLoS Negl. Trop. Dis. 9, e0003736 (2015).
Google Scholar
Bredenbeek, P. J. et al. A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins. Virology 345, 299–304 (2006).
Google Scholar
Jiang, X. et al. Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs. Vaccine 29, 1248–1257 (2011).
Google Scholar
Lukashevich, I. S. & Pushko, P. Vaccine platforms to control Lassa fever. Expert Rev. Vaccines 15, 1135–1150, (2016).
Google Scholar
Frantz, P. N., Teeravechyan, S. & Tangy, F. Measles-derived vaccines to prevent emerging viral diseases. Microbes Infect. 20, 493–500 (2018).
Google Scholar
Mateo, M. et al. One-shot immunization using a Measles/Lassa vaccine fully protects cynomolgus monkeys against Lassa fever. Int J Infect Dis. 79, 6 (2019).
Clegg, J. C. & Lloyd, G. Vaccinia recombinant expressing Lassa-virus internal nucleocapsid protein protects guineapigs against Lassa fever. Lancet 2, 186–188, (1987).
Google Scholar
Fisher-Hoch, S. P., Hutwagner, L., Brown, B. & McCormick, J. B. Effective vaccine for lassa fever. J. Virol. 74, 6777–6783 (2000).
Google Scholar
Salvato, M. S. et al. A Single Dose of Modified Vaccinia Ankara Expressing Lassa Virus-like Particles Protects Mice from Lethal Intra-cerebral Virus Challenge. Pathogens 8, 133 (2019).
Google Scholar
Pushko, P. et al. Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. J. Virol. 75, 11677–11685 (2001).
Google Scholar
Wang, M. et al. Alphavirus vector-based replicon particles expressing multivalent cross-protective Lassa virus glycoproteins. Vaccine 36, 683–690 (2018).
Google Scholar
Maruyama, J. et al. Adenoviral vector-based vaccine is fully protective against lethal Lassa fever challenge in Hartley guinea pigs. Vaccine 37, 6824–6831 (2019).
Google Scholar
Cashman, K. A. et al. Enhanced Efficacy of a Codon-Optimized DNA Vaccine Encoding the Glycoprotein Precursor Gene of Lassa Virus in a Guinea Pig Disease Model When Delivered by Dermal Electroporation. Vaccines 1, 262–277 (2013).
Google Scholar
Cashman, K. A. et al. A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against Lassa fever. Hum. Vaccin Immunother. 13, 2902–2911 (2017).
Google Scholar
Jiang, J. et al. Immunogenicity of a protective intradermal DNA vaccine against lassa virus in cynomolgus macaques. Hum. Vaccin Immunother. 15, 2066–2074 (2019).
Google Scholar
Kotturi, M. F. et al. A multivalent and cross-protective vaccine strategy against arenaviruses associated with human disease. PLoS Pathog. 5, e1000695 (2009).
Google Scholar
Botten, J. et al. A multivalent vaccination strategy for the prevention of Old World arenavirus infection in humans. J. Virol. 84, 9947–9956 (2010).
Google Scholar
Leifer, E., Gocke, D. J. & Bourne, H. Lassa fever, a new virus disease of man from West Africa. II. Report of a laboratory-acquired infection treated with plasma from a person recently recovered from the disease. Am. J. Trop. Med. Hyg. 19, 677–679 (1970).
Google Scholar
Jahrling, P. B. Protection of Lassa virus-infected guinea pigs with Lassa-immune plasma of guinea pig, primate, and human origin. J. Med. Virol. 12, 93–102 (1983).
Google Scholar
Frame, J. D., Verbrugge, G. P., Gill, R. G. & Pinneo, L. The use of Lassa fever convalescent plasma in Nigeria. Trans. R. Soc. Trop. Med. Hyg. 78, 319–324 (1984).
Google Scholar
McCormick, J. B. Clinical, epidemiologic, and therapeutic aspects of Lassa fever. Med. Microbiol. Immunol. 175, 153–155 (1986).
Google Scholar
Jahrling, P. B. et al. Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin. J. Infect. Dis. 141, 580–589 (1980).
Google Scholar
Ter Meulen, J. et al. Hunting of peridomestic rodents and consumption of their meat as possible risk factors for rodent-to-human transmission of Lassa virus in the Republic of Guinea. Am. J. Trop. Med. Hyg. 55, 661–666 (1996).
Google Scholar
Houlihan, C. & Behrens, R. Lassa fever. BMJ 358, j2986 (2017).
Google Scholar
Carrillo-Bustamante, P. et al. Determining Ribavirin’s mechanism of action against Lassa virus infection. Sci. Rep. 7, 11693 (2017).
Google Scholar
Madu, I. G. et al. A potent Lassa virus antiviral targets an arenavirus virulence determinant. PLoS Pathog. 14, e1007439 (2018).
Google Scholar
Ruo, S. L. et al. Antigenic relatedness between arenaviruses defined at the epitope level by monoclonal antibodies. J. Gen. Virol. 72, 549–555 (1991).
Google Scholar
Cross, R. W. et al. A human monoclonal antibody combination rescues nonhuman primates from advanced disease caused by the major lineages of Lassa virus. Proc. Natl Acad. Sci. USA 120, e2304876120 (2023).
Google Scholar
Zhong, N. S. et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People’s Republic of China, in February, 2003. Lancet 362, 1353–1358 (2003).
Google Scholar
Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273 (2020).
Google Scholar
Zaki, A. M. et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 367, 1814–1820 (2012).
Google Scholar
Rabaan, A. A. et al. SARS-CoV-2, SARS-CoV, and MERS-COV: A comparative overview. Le. Infez. Med. 28, 174–184 (2020).
Google Scholar
Cui, J., Li, F. & Shi, Z. L. Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol 17, 181–192 (2019).
Google Scholar
Walls, A. C. et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 181, 281–292.e286 (2020).
Google Scholar
Li, W. et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426, 450–454 (2003).
Google Scholar
Wang, Q. et al. Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. Cell 181, 894–904.e899 (2020).
Google Scholar
Arabi, Y. M. et al. Middle East Respiratory Syndrome. N. Engl. J. Med. 376, 584–594 (2017).
Google Scholar
Cron, R. Q., Caricchio, R. & Chatham, W. W. Calming the cytokine storm in COVID-19. Nat. Med. 27, 1674–1675 (2021).
Google Scholar
Shang, J. et al. Structural basis of receptor recognition by SARS-CoV-2. Nature 581, 221–224 (2020).
Google Scholar
Jiang, R.-D. et al. Pathogenesis of SARS-CoV-2 in transgenic mice expressing human angiotensin-converting enzyme 2. Cell 182, 50–58 (2020).
Google Scholar
McCray, P. B. Jr. et al. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J. Virol. 81, 813–821 (2007).
Google Scholar
Li, K. et al. Middle East Respiratory Syndrome Coronavirus Causes Multiple Organ Damage and Lethal Disease in Mice Transgenic for Human Dipeptidyl Peptidase 4. J. Infect. Dis. 213, 712–722 (2016).
Google Scholar
Zheng, J. et al. COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice. Nature 589, 603–607 (2021).
Google Scholar
Yinda, C. K. et al. K18-hACE2 mice develop respiratory disease resembling severe COVID-19. PLoS Pathog. 17, e1009195 (2021).
Google Scholar
Winkler, E. S. et al. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat. Immunol. 21, 1327–1335 (2020).
Google Scholar
Sun, S. H. et al. A Mouse Model of SARS-CoV-2 Infection and Pathogenesis. Cell Host Microbe 28, 124–133.e124 (2020).
Google Scholar
Hong, W. et al. A mouse model for SARS-CoV-2-induced acute respiratory distress syndrome. Signal Transduct. Target Ther. 6, 1 (2021).
Google Scholar
Agrawal, A. S. et al. Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease. J. Virol. 89, 3659–3670 (2015).
Google Scholar
Zhao, G. et al. Multi-Organ Damage in Human Dipeptidyl Peptidase 4 Transgenic Mice Infected with Middle East Respiratory Syndrome-Coronavirus. PLoS One 10, e0145561 (2015).
Google Scholar
Tao, X. et al. Characterization and Demonstration of the Value of a Lethal Mouse Model of Middle East Respiratory Syndrome Coronavirus Infection and Disease. J. Virol. 90, 57–67 (2016).
Google Scholar
Pascal, K. E. et al. Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection. Proc. Natl Acad. Sci. USA 112, 8738–8743 (2015).
Google Scholar
Cockrell, A. S. et al. A mouse model for MERS coronavirus-induced acute respiratory distress syndrome. Nat. Microbiol 2, 16226 (2016).
Google Scholar
Kim, J., Yang, Y. L., Jeong, Y. & Jang, Y. S. Middle East Respiratory Syndrome-Coronavirus Infection into Established hDPP4-Transgenic Mice Accelerates Lung Damage Via Activation of the Pro-Inflammatory Response and Pulmonary Fibrosis. J. Microbiol. Biotechnol. 30, 427–438 (2020).
Google Scholar
Hassan, A. O. et al. A SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies. Cell 182, 744–753.e744 (2020).
Google Scholar
Sun, J. et al. Generation of a Broadly Useful Model for COVID-19 Pathogenesis Vaccination, and Treatment. Cell 182, 734–743.e735 (2020).
Google Scholar
Zhao, J. et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc. Natl Acad. Sci. USA 111, 4970–4975 (2014).
Google Scholar
Israelow, B. et al. Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling. J. Exp. Med. 217, e20201241 (2020).
Google Scholar
Yang, M. S. et al. Non-invasive administration of AAV to target lung parenchymal cells and develop SARS-CoV-2-susceptible mice. Mol. Ther. 30, 1994–2004 (2022).
Google Scholar
Sefik, E. et al. A humanized mouse model of chronic COVID-19. Nat. Biotechnol. 40, 906–920 (2022).
Google Scholar
Sefik, E. et al. Inflammasome activation in infected macrophages drives COVID-19 pathology. Nature 606, 585–593 (2022).
Google Scholar
Roberts, A. et al. A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice. PLoS Pathog. 3, e5 (2007).
Google Scholar
Li, K. et al. Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice. Proc. Natl Acad. Sci. USA 114, E3119–e3128 (2017).
Google Scholar
Gu, H. et al. Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy. Science, 369, 1603–1607 (2020).
Wang et al. Mouse-adapted SARS-CoV-2 replicates efficiently in the upper and lower respiratory tract of BALB/c and C57BL/6J mice. Protein Cell 11, 776–782 (2020).
Google Scholar
Leist, S. R. et al. A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice. Cell 183, 1070–1085.e1012 (2020).
Google Scholar
Yan, F. et al. Characterization of Two Heterogeneous Lethal Mouse-Adapted SARS-CoV-2 Variants Recapitulating Representative Aspects of Human COVID-19. Front. Immunol. 13, 821664 (2022).
Google Scholar
Ng, D. L. et al. Clinicopathologic, Immunohistochemical, and Ultrastructural Findings of a Fatal Case of Middle East Respiratory Syndrome Coronavirus Infection in the United Arab Emirates, April 2014. Am. J. Pathol. 186, 652–658 (2016).
Google Scholar
Iwata-Yoshikawa, N. et al. Acute Respiratory Infection in Human Dipeptidyl Peptidase 4-Transgenic Mice Infected with Middle East Respiratory Syndrome Coronavirus. J. Virol. 93, e01818–e01818 (2019).
Google Scholar
Coleman, C. M. et al. CD8+ T Cells and Macrophages Regulate Pathogenesis in a Mouse Model of Middle East Respiratory Syndrome. J. Virol. 91, e01825-16 (2017).
Singh, A. et al. A Comprehensive Review of Animal Models for Coronaviruses: SARS-CoV-2, SARS-CoV, and MERS-CoV. Virol. Sin. 35, 290–304 (2020).
Google Scholar
Liu, Y. H. et al. Functional and genetic analysis of viral receptor ACE2 orthologs reveals a broad potential host range of SARS-CoV-2. Proc. Natl Acad. Sci. USA 118, e2025373118 (2021).
Google Scholar
Zhao, X. S. et al. Broad and Differential Animal Angiotensin-Converting Enzyme 2 Receptor Usage by SARS-CoV-2. J. Virol. 94, e00940–00920 (2020).
Google Scholar
Ma, H. et al. A bispecific nanobody dimer broadly neutralizes SARS-CoV-1 & 2 variants of concern and offers substantial protection against Omicron via low-dose intranasal administration. Cell Discov. 8, 132 (2022).
Google Scholar
Lu, G. et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 500, 227–231 (2013).
Google Scholar
Roberts, A. et al. Severe Acute Respiratory Syndrome Coronavirus Infection of Golden Syrian Hamsters. J. Virol. 79, 503–511 (2005).
Google Scholar
Roberts, A. et al. Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters. J. Infect. Dis. 193, 685–692 (2006).
Google Scholar
Schaecher, S. R. et al. An immunosuppressed Syrian golden hamster model for SARS-CoV infection. Virology 380, 312–321 (2008).
Google Scholar
Sia, S. F. et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature 583, 834–838 (2020).
Google Scholar
Chan, J. F. et al. Simulation of the Clinical and Pathological Manifestations of Coronavirus Disease 2019 (COVID-19) in a Golden Syrian Hamster Model: Implications for Disease Pathogenesis and Transmissibility. Clin. Infect. Dis. 71, 2428–2446 (2020).
Google Scholar
Imai, M. et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc. Natl Acad. Sci. USA 117, 16587–16595 (2020).
Google Scholar
Bakoyiannis, I. Cardiovascular effects of SARS-CoV-2 in hamster. Lab. Anim. 51, 77 (2022).
Rizvi, Z. A. et al. Golden Syrian hamster as a model to study cardiovascular complications associated with SARS-CoV-2 infection. Elife 11, e73522 (2022).
Google Scholar
Yuan, L. et al. Infection, pathology and interferon treatment of the SARS-CoV-2 Omicron BA.1 variant in juvenile, adult and aged Syrian hamsters. Cell. Mol. Immunol. 19, 1392–1399 (2022).
Google Scholar
Osterrieder, N. et al. Age-Dependent Progression of SARS-CoV-2 Infection in Syrian Hamsters. Viruses 12, 779 (2020).
Google Scholar
Ohno, M. et al. Abnormal Blood Coagulation and Kidney Damage in Aged Hamsters Infected with Severe Acute Respiratory Syndrome Coronavirus 2. Viruses 13, 2137 (2021).
Google Scholar
Santosh, D. et al. Sex Differences in Lung Imaging and SARS-CoV-2 Antibody Responses in a COVID-19 Golden Syrian Hamster Model. mBio. 12, e0097421 (2021).
Google Scholar
Li, C. et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection by Intranasal or Intratesticular Route Induces Testicular Damage. Clin. Infect. Dis. 75, e974–e990 (2022).
Google Scholar
Yuan, L. et al. Persisting lung pathogenesis and minimum residual virus in hamster after acute COVID-19. Protein Cell 13, 72–77 (2022).
Google Scholar
Golden, J. W. et al. Hamsters Expressing Human Angiotensin-Converting Enzyme 2 Develop Severe Disease following Exposure to SARS-CoV-2. mBio 13, e0290621 (2022).
Google Scholar
Zhai, C. et al. Roborovski hamster (Phodopus roborovskii) strain SH101 as a systemic infection model of SARS-CoV-2. Virulence 12, 2430–2442 (2021).
Google Scholar
Trimpert, J. et al. The Roborovski Dwarf Hamster Is A Highly Susceptible Model for a Rapid and Fatal Course of SARS-CoV-2 Infection. Cell Rep. 33, 108488 (2020).
Google Scholar
Bertzbach, L. D. et al. SARS-CoV-2 infection of Chinese hamsters (Cricetulus griseus) reproduces COVID-19 pneumonia in a well-established small animal model. Transbound. Emerg. Dis. 68, 1075–1079 (2021).
Google Scholar
Rosenke, K. et al. Defining the Syrian hamster as a highly susceptible preclinical model for SARS-CoV-2 infection. Emerg. Microbes Infect. 9, 2673-2684, (2020).
Boudewijns, R. et al. STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters. Nat. Commun. 11, 5838 (2020).
Google Scholar
Brocato, R. L. et al. Disruption of Adaptive Immunity Enhances Disease in SARS-CoV-2-Infected Syrian Hamsters. J. Virol. 94, e01683–01620 (2020).
Google Scholar
van Doremalen, N. et al. Host species restriction of Middle East respiratory syndrome coronavirus through its receptor, dipeptidyl peptidase 4. J. Virol. 88, 9220–9232 (2014).
Google Scholar
Martina, B. E. E. et al. Virology: SARS virus infection of cats and ferrets. Nature 425, 915 (2003).
Google Scholar
Weingartl, H. et al. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J. Virol. 78, 12672–12676 (2004).
Google Scholar
Darnell, M. E. R. et al. Severe acute respiratory syndrome coronavirus infection in vaccinated ferrets. J. Infect. Dis. 196, 1329–1338 (2007).
Google Scholar
Chu, Y.-K. et al. The SARS-CoV ferret model in an infection-challenge study. Virology 374, 151–163 (2008).
Google Scholar
Kim, Y. I. et al. Infection and Rapid Transmission of SARS-CoV-2 in Ferrets. Cell Host Microbe 27, 704–709 e702 (2020).
Google Scholar
Monchatre-Leroy, E. et al. Hamster and ferret experimental infection with intranasal low dose of a single strain of SARS-CoV-2. J. Gen. Virol. 102, 001567 (2021).
Google Scholar
Kutter, J. S. et al. SARS-CoV and SARS-CoV-2 are transmitted through the air between ferrets over more than one meter distance. Nat. Commun. 12, 1653 (2021).
Google Scholar
Everett, H. E. et al. Intranasal Infection of Ferrets with SARS-CoV-2 as a Model for Asymptomatic Human Infection. Viruses 13, 113 (2021).
Google Scholar
Pulit-Penaloza, J. A. et al. Comparative Assessment of Severe Acute Respiratory Syndrome Coronavirus 2 Variants in the Ferret Model. mBio 13, e0242122 (2022).
Google Scholar
Ryan, K. A. et al. Dose-dependent response to infection with SARS-CoV-2 in the ferret model and evidence of protective immunity. Nat. Commun. 12, 81 (2021).
Google Scholar
Martins, M., Fernandes, M. H. V., Joshi, L. R. & Diel, D. G. Age-Related Susceptibility of Ferrets to SARS-CoV-2 Infection. J. Virol. 96, e0145521 (2022).
Google Scholar
Kim, Y.-I. et al. Age-dependent pathogenic characteristics of SARS-CoV-2 infection in ferrets. Nat. Commun. 13, 21 (2022).
Google Scholar
Shi, Z. & Hu, Z. A review of studies on animal reservoirs of the SARS coronavirus. Virus Res. 133, 74–87 (2008).
Google Scholar
Oreshkova, N. et al. SARS-CoV-2 infection in farmed minks, the Netherlands, April and May 2020. Eur. Surveill. 25, 2001005 (2020).
Google Scholar
Shuai, L. et al. Replication, pathogenicity, and transmission of SARS-CoV-2 in minks. Natl Sci. Rev. 8, nwaa291 (2021).
Google Scholar
Hammer, A. S. et al. SARS-CoV-2 Transmission between Mink (Neovison vison) and Humans, Denmark. Emerg. Infect. Dis. 27, 547–551 (2021).
Google Scholar
Adney, D. R. et al. Severe acute respiratory disease in American mink experimentally infected with SARS-CoV-2. JCI Insight 7, e159573 (2022).
Google Scholar
Ritter, J. M. et al. Histopathology and localization of SARS-CoV-2 and its host cell entry receptor ACE2 in tissues from naturally infected US-farmed mink (Neovison vison). Vet. Pathol. 59, 681–695 (2022).
Google Scholar
Virtanen, J. et al. Experimental Infection of Mink with SARS-COV-2 Omicron Variant and Subsequent Clinical Disease. Emerg. Infect. Dis. 28, 1286–1288 (2022).
Google Scholar
Song, Z. et al. Integrated histopathological, lipidomic, and metabolomic profiles reveal mink is a useful animal model to mimic the pathogenicity of severe COVID-19 patients. Signal Transduct. Target Ther. 7, 29 (2022).
Google Scholar
de Wit, E. et al. Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. Proc. Natl Acad. Sci. USA 110, 16598–16603 (2013).
Google Scholar
Falzarano, D. et al. Infection with MERS-CoV causes lethal pneumonia in the common marmoset. PLoS Pathog. 10, e1004250 (2014).
Google Scholar
Lu, S. et al. Comparison of nonhuman primates identified the suitable model for COVID-19. Signal Transduct. Target Ther. 5, 157 (2020).
Google Scholar
Tong, D. et al. Single-dose AAV-based vaccine induces a high level of neutralizing antibodies against SARS-CoV-2 in rhesus macaques. Protein Cell 14, 69–73 (2023).
Google Scholar
Munster, V. J. et al. Subtle differences in the pathogenicity of SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in rhesus macaques. Sci. Adv. 7, eabj3627 (2021).
Google Scholar
Haagmans, B. L. & Osterhaus, A. D. M. E. Nonhuman primate models for SARS. PLoS Med. 3, e194 (2006).
Google Scholar
Rowe, T. et al. Macaque model for severe acute respiratory syndrome. J. Virol. 78, 11401–11404 (2004).
Google Scholar
McAuliffe, J. et al. Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys. Virology 330, 8–15 (2004).
Google Scholar
Lawler, J. V. et al. Cynomolgus macaque as an animal model for severe acute respiratory syndrome. PLoS Med. 3, e149 (2006).
Google Scholar
Rockx, B. et al. Comparative pathogenesis of three human and zoonotic SARS-CoV strains in cynomolgus macaques. PLoS One 6, e18558 (2011).
Google Scholar
de Lang, A. et al. Functional genomics highlights differential induction of antiviral pathways in the lungs of SARS-CoV-infected macaques. PLoS Pathog. 3, e112 (2007).
Google Scholar
Smits, S. L. et al. Distinct severe acute respiratory syndrome coronavirus-induced acute lung injury pathways in two different nonhuman primate species. J. Virol. 85, 4234–4245 (2011).
Google Scholar
Nagata, N. et al. Pathology and virus dispersion in cynomolgus monkeys experimentally infected with severe acute respiratory syndrome coronavirus via different inoculation routes. Int. J. Exp. Pathol. 88, 403–414 (2007).
Google Scholar
Rockx, B. et al. Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. Science 368, 1012–1015 (2020).
Google Scholar
Baek, S. H. et al. Cynomolgus Macaque Model for COVID-19 Delta Variant. Immune Netw. 22, e48 (2022).
Google Scholar
Johnston, S. C. et al. Development of a coronavirus disease 2019 nonhuman primate model using airborne exposure. PLoS One 16, e0246366 (2021).
Google Scholar
Dabisch, P. A. et al. Seroconversion and fever are dose-dependent in a nonhuman primate model of inhalational COVID-19. PLoS Pathog. 17, e1009865 (2021).
Google Scholar
Salguero, F. J. et al. Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19. Nat. Commun. 12, 1260 (2021).
Google Scholar
Urano, E. et al. COVID-19 cynomolgus macaque model reflecting human COVID-19 pathological conditions. Proc. Natl Acad. Sci. USA 118, e2104847118 (2021).
Google Scholar
Wang, T. et al. Proteomic and Metabolomic Characterization of SARS-CoV-2-Infected Cynomolgus Macaque at Early Stage. Front. Immunol. 13, 954121 (2022).
Google Scholar
Woolsey, C. et al. Establishment of an African green monkey model for COVID-19 and protection against re-infection. Nat. Immunol. 22, 86–98 (2021).
Google Scholar
Blair, R. V. et al. Acute Respiratory Distress in Aged, SARS-CoV-2-Infected African Green Monkeys but Not Rhesus Macaques. Am. J. Pathol. 191, 274–282 (2021).
Google Scholar
Singh, D. K. et al. Responses to acute infection with SARS-CoV-2 in the lungs of rhesus macaques, baboons and marmosets. Nat. Microbiol 6, 73–86 (2021).
Google Scholar
Mercado, N. B. et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature 590, E25 (2020).
Google Scholar
Corbett, K. S. et al. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N. Engl. J. Med. 383, 1544–1555 (2020).
Google Scholar
Vogel, A. B. et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature 592, 283–289 (2021).
Google Scholar
Muñoz-Fontela, C. et al. Advances and gaps in SARS-CoV-2 infection models. PLoS Pathog. 18, e1010161 (2022).
Google Scholar
Chandrashekar, A. et al. Prior infection with SARS-CoV-2 WA1/2020 partially protects rhesus macaques against reinfection with B.1.1.7 and B.1.351 variants. Sci. Transl. Med. 13, eabj2641 (2021).
Google Scholar
Gao, Q. et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science 369, 77–81 (2020).
Google Scholar
Wu, Z. et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 21, 803–812 (2021).
Wang, H. et al. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell 182, 713–721 (2020).
Google Scholar
Graham, R. L., Donaldson, E. F. & Baric, R. S. A decade after SARS: strategies for controlling emerging coronaviruses. Nat. Rev. Microbiol. 11, 836–848 (2013).
Google Scholar
Zhou, Y., Jiang, S. & Du, L. Prospects for a MERS-CoV spike vaccine. Expert Rev. Vaccines 17, 677–686 (2018).
Google Scholar
He, Y. et al. Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines. J. Immunol. 173, 4050–4057 (2004).
Google Scholar
Richmond, P. et al. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial. Lancet 397, 682–694 (2021).
Google Scholar
Bravo, L. et al. Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial. Lancet 399, 461–472 (2022).
Google Scholar
Dunkle, L. M. et al. Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico. N. Engl. J. Med. 386, 531–543 (2022).
Google Scholar
Dai, L. et al. A universal design of betacoronavirus vaccines against COVID-19, MERS and SARS. Cell 182, 722–733.e11 (2020).
Google Scholar
Yang, S. et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect. Dis. 21, 1107–1119 (2021).
Google Scholar
Xu, K. et al. Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2. Cell 185, 2265–2278.e2214 (2022).
Google Scholar
Dai, L. et al. Efficacy and Safety of the RBD-Dimer-Based Covid-19 Vaccine ZF2001 in Adults. N. Engl. J. Med. 386, 2097–2111 (2022).
Google Scholar
Gao, L. et al. Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial. Lancet Child Adolesc. Health 7, 269–279 (2023).
Google Scholar
Walls, A. C. et al. Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2. Cell 183, 1367–1382.e17 (2020).
Google Scholar
Travieso, T. et al. The use of viral vectors in vaccine development. NPJ Vaccines 7, 75 (2022).
Google Scholar
Ewer, K. J. et al. Viral vectors as vaccine platforms: from immunogenicity to impact. Curr. Opin. Immunol. 41, 47–54 (2016).
Google Scholar
Halperin, S. A. et al. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial. Lancet 399, 237–248 (2022).
Google Scholar
Sadoff, J. et al. Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S. N. Engl. J. Med. 386, 847–860 (2022).
Google Scholar
Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397, 99–111 (2021).
Google Scholar
Zhu, F. et al. Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Respir. Med. 10, 749–760 (2022).
Google Scholar
Logunov, D. Y. et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 397, 671–681 (2021).
Google Scholar
Robbins, J. A. et al. Safety and immunogenicity of intramuscular, single-dose V590 (rVSV-SARS-CoV-2 Vaccine) in healthy adults: Results from a phase 1 randomised, double-blind, placebo-controlled, dose-ranging trial. eBioMedicine 82, 104138 (2022).
Google Scholar
Wang, S. et al. Characterization of Immune Response Diversity in Rodents Vaccinated with a Vesicular Stomatitis Virus Vectored COVID-19 Vaccine. Viruses 14, 1127 (2022).
Google Scholar
Wang, S. et al. Oral delivery of a chitosan adjuvanted COVID-19 vaccine provides long-lasting and broad-spectrum protection against SARS-CoV-2 variants of concern in golden hamsters. Antivir. Res. 220, 105765 (2023).
Google Scholar
Kapadia, S. U. et al. Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology 340, 174–182 (2005).
Google Scholar
Schmidt, A. C. et al. Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates. J. Virol. 74, 8922–8929 (2000).
Google Scholar
Karron, R. A. et al. Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children. Vaccine 30, 3975–3981 (2012).
Google Scholar
Buchholz, U. J. et al. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc. Natl Acad. Sci. USA 101, 9804–9809 (2004).
Google Scholar
Ohtsuka, J. et al. Non-propagative human parainfluenza virus type 2 nasal vaccine robustly protects the upper and lower airways against SARS-CoV-2. iScience 24, 103379 (2021).
Google Scholar
An, D. et al. Protection of K18-hACE2 mice and ferrets against SARS-CoV-2 challenge by a single-dose mucosal immunization with a parainfluenza virus 5-based COVID-19 vaccine. Sci. Adv. 7, eabi5246 (2021).
Google Scholar
Liu, X. et al. A single intranasal dose of a live-attenuated parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in hamsters. Proc. Natl Acad. Sci. USA 118, e2109744118 (2021).
Google Scholar
Le Nouën, C. et al. Intranasal pediatric parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in monkeys. Cell 185, 4811–4825.e4817 (2022).
Google Scholar
Ilinykh, P. A. et al. A single intranasal dose of human parainfluenza virus type 3-vectored vaccine induces effective antibody and memory T cell response in the lungs and protects hamsters against SARS-CoV-2. NPJ Vaccines 7, 47 (2022).
Google Scholar
Wang, P. et al. Generation of DelNS1 Influenza Viruses: a Strategy for Optimizing Live Attenuated Influenza Vaccines. mBio 10, e02180–02119 (2019).
Google Scholar
Chen, J. et al. A live attenuated virus-based intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2. Sci. Bull. 67, 1372–1387 (2022).
Google Scholar
Zhu, F. et al. Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir. Med. 11, 1075–1088 (2023).
Google Scholar
Zhu, F.-C. et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet 395, 1845–1854 (2020).
Google Scholar
Zhu, F.-C. et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 396, 479–488 (2020).
Google Scholar
Li, J. X. et al. Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial. Lancet Respir. Med. 10, 739–748 (2022).
Google Scholar
Li, J. et al. Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial. Nat. Med. 28, 401–409 (2022).
Google Scholar
Jin, L. et al. Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial. Emerg. Microbes Infect. 12, 2155251 (2023).
Google Scholar
Tukhvatulin, A. I. et al. An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine “Sputnik Light” for prevention of coronavirus infection in healthy adults. Lancet Reg. Health Eur. 11, 100241 (2021).
Google Scholar
Voysey, M. et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet 397, 881–891 (2021).
Google Scholar
Jenkin, D. et al. Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nat. Med. 27, 279–288 (2020).
Google Scholar
Logunov, D. Y. et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet 396, 887–897 (2020).
Google Scholar
Weskamm, L. M. et al. Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine. Cell Rep. Med. 3, 100685 (2022).
Google Scholar
Song, F. et al. Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies. J. Virol. 87, 11950–11954 (2013).
Google Scholar
Folegatti, P. M. et al. Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. Lancet Infect. Dis. 20, 816–826 (2020).
Google Scholar
García-Arriaza, J. et al. COVID-19 vaccine candidates based on modified vaccinia virus Ankara expressing the SARS-CoV-2 spike induce robust T- and B-cell immune responses and full efficacy in mice. J. Virol. 95, e02260–02220 (2021).
Google Scholar
Fang, E. et al. Advances in COVID-19 mRNA vaccine development. Signal Transduct. Target Ther. 7, 94 (2022).
Google Scholar
Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines – a new era in vaccinology. Nat. Rev. Drug Discov. 17, 261–279 (2018).
Google Scholar
Sahin, U. et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. medRxiv, (2020).
Polack, F. P. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 383, 2603–2615 (2020).
Google Scholar
Walsh, E. E. et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N. Engl. J. Med. 383, 2439–2450 (2020).
Google Scholar
Widge, A. T. et al. Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. N. Engl. J. Med. 384, 80–82 (2021).
Google Scholar
Zhang, N.-N. et al. A thermostable mRNA vaccine against COVID-19. Cell 182, 1271–1283.e1216 (2020).
Google Scholar
Chen, G. L. et al. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Microbe 3, e193–e202 (2022).
Google Scholar
Li, L. et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA 324, 460–470 (2020).
Google Scholar
Focosi, D., Anderson, A. O., Tang, J. W. & Tuccori, M. Convalescent Plasma Therapy for COVID-19: State of the Art. Clin. Microbiol. Rev. 33, e00072–20 (2020).
Google Scholar
Chen, Y. et al. Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses. Nat. Rev. Immunol. 23, 189–199 (2023).
Google Scholar
Taylor, P. C. et al. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat. Rev. Immunol. 21, 382–393 (2021).
Google Scholar
Leisman, D. E. et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir. Med. 8, 1233–1244 (2020).
Google Scholar
Giamarellos-Bourboulis, E. J. et al. Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure. Cell Host Microbe 27, 992–1000.e1003 (2020).
Google Scholar
Xu, X. et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc. Natl Acad. Sci. USA 117, 10970–10975 (2020).
Google Scholar
Salama, C. et al. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. N. Engl. J. Med. 384, 20–30 (2021).
Google Scholar
Rosas, I. O. et al. Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. N. Engl. J. Med. 384, 1503–1516 (2021).
Google Scholar
Tatham, K. C., Shankar-Hari, M. & Arabi, Y. M. The REMDACTA trial: do interleukin receptor antagonists provide additional benefit in COVID-19? Intensive Care Med. 47, 1315–1318 (2021).
Google Scholar
Chen, P. et al. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. N. Engl. J. Med. 384, 229–237 (2021).
Google Scholar
Hansen, J. et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science, 369, 1010–1014, (2020).
Baum, A. et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science, 369, 1014–1018 (2020).
Baum, A. et al. REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. Science 370, 1110–1115 (2020).
Google Scholar
Weinreich, D. M. et al. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. N. Engl. J. Med. 384, 238–251 (2021).
Google Scholar
Weinreich, D. M. et al. REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19. N. Engl. J. Med. 385, e81 (2021).
Google Scholar
Shi, R. et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature 584, 120–124 (2020).
Google Scholar
Dougan, M. et al. Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19. N. Engl. J. Med. 385, 1382–1392 (2021).
Google Scholar
Gottlieb, R. L. et al. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA 325, 632–644 (2021).
Google Scholar
Hoy, S. M. Amubarvimab/Romlusevimab: First Approval. Drugs 82, 1327–1331 (2022).
Google Scholar
Evering, T. H. et al. Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19. Ann. Intern. Med. 176, 658–666 (2023).
Google Scholar
ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. Lancet Infect. Dis. 22, 622–635, (2022).
Chi, X. et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science 369, 650–655 (2020).
Google Scholar
Suryadevara, N. et al. Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein. Cell 184, 2316–2331.e2315 (2021).
Google Scholar
Liu, L. et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584, 450–456 (2020).
Google Scholar
Lok, S. M. An NTD supersite of attack. Cell Host Microbe 29, 744–746 (2021).
Google Scholar
Cerutti, G. et al. Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite. Cell Host Microbe 29, 819–833.e817 (2021).
Google Scholar
Pinto, D. et al. Broad betacoronavirus neutralization by a stem helix-specific human antibody. Science 373, 1109–1116 (2021).
Google Scholar
Dacon, C. et al. Broadly neutralizing antibodies target the coronavirus fusion peptide. Science 377, 728–735 (2022).
Google Scholar
Sun, X. et al. Neutralization mechanism of a human antibody with pan-coronavirus reactivity including SARS-CoV-2. Nat. Microbiol. 7, 1063–1074 (2022).
Google Scholar
Zhou, P. et al. A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection. Sci. Transl. Med. 14, eabi9215 (2022).
Google Scholar
Cao, Y. et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 602, 657–663 (2022).
Google Scholar
Zost, S. J. et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature 584, 443–449 (2020).
Google Scholar
Hanke, L. et al. A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo. Nat. Commun. 13, 155 (2022).
Google Scholar
Tian, D. et al. An update review of emerging small-molecule therapeutic options for COVID-19. Biomed. Pharmacother. 137, 111313 (2021).
Google Scholar
Lei, S. et al. Small molecules in the treatment of COVID-19. Signal Transduct. Target Ther. 7, 387 (2022).
Google Scholar
Kokic, G. et al. Mechanism of SARS-CoV-2 polymerase stalling by remdesivir. Nat. Commun. 12, 279 (2021).
Google Scholar
Yin, W. et al. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science 368, 1499–1504 (2020).
Google Scholar
Rochwerg, B. et al. Remdesivir for severe covid-19: a clinical practice guideline. BMJ 370, m2924 (2020).
Google Scholar
Gottlieb, R. L. et al. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. N. Engl. J. Med. 386, 305–315 (2022).
Google Scholar
Amstutz, A. et al. Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials. Lancet Respir. Med. 11, 453–464 (2023).
Google Scholar
Kabinger, F. et al. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat. Struct. Mol. Biol. 28, 740–746 (2021).
Google Scholar
Fischer, W. A. 2nd et al. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. Sci. Transl. Med. 14, eabl7430 (2022).
Google Scholar
Jayk Bernal, A. et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N. Engl. J. Med. 386, 509–520 (2022).
Google Scholar
Cao, Z. et al. VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19. N. Engl. J. Med. 388, 406–417 (2023).
Google Scholar
Joshi, S. et al. Role of favipiravir in the treatment of COVID-19. Int. J. Infect. Dis. 102, 501–508 (2021).
Google Scholar
Qian, H. J. et al. Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against SARS-CoV-2, in Chinese healthy subjects. Acta Pharm. Sin. 43, 3130–3138 (2022).
Google Scholar
Hammond, J. et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N. Engl. J. Med. 386, 1397–1408 (2022).
Google Scholar
Patel, N. M. et al. Inhibition of the JAK/STAT Pathway With Baricitinib Reduces the Multiple Organ Dysfunction Caused by Hemorrhagic Shock in Rats. Ann. Surg. 278, e137–e146 (2023).
Google Scholar
Bronte, V. et al. Baricitinib restrains the immune dysregulation in patients with severe COVID-19. J. Clin. Invest. 130, 6409–6416 (2020).
Google Scholar
Marconi, V. C. et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir. Med. 9, 1407–1418 (2021).
Google Scholar
Lamb, Y. N. Remdesivir: First Approval. Drugs 80, 1355–1363 (2020).
Google Scholar
Kalil, A. C. et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N. Engl. J. Med. 384, 795–807 (2021).
Google Scholar
Cadegiani, F. A. et al. Final Results of a Randomized, Placebo-Controlled, Two-Arm, Parallel Clinical Trial of Proxalutamide for Hospitalized COVID-19 Patients: A Multiregional, Joint Analysis of the Proxa-Rescue AndroCoV Trial. Cureus 13, e20691 (2021).
Google Scholar
John, M. et al. Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial. Front. Med. 9, 964099 (2022).
Google Scholar
Mendoza, E. J., Warner, B., Safronetz, D. & Ranadheera, C. Crimean-Congo haemorrhagic fever virus: Past, present and future insights for animal modelling and medical countermeasures. Zoonoses Public Health 65, 465–480 (2018).
Google Scholar
Whitehouse, C. A. Crimean-Congo hemorrhagic fever. Antivir. Res. 64, 145–160 (2004).
Google Scholar
Durie, I. A. et al. Structural characterization of protective non-neutralizing antibodies targeting Crimean-Congo hemorrhagic fever virus. Nat. Commun. 13, 7298 (2022).
Google Scholar
Zivcec, M. et al. Identification of broadly neutralizing monoclonal antibodies against Crimean-Congo hemorrhagic fever virus. Antivir. Res. 146, 112–120 (2017).
Google Scholar
Casals, J. Antigenic similarity between the virus causing Crimean hemorrhagic fever and Congo virus. Proc. Soc. Exp. Biol. Med. 131, 233–236 (1969).
Google Scholar
Serretiello, E. et al. The emerging tick-borne Crimean-Congo haemorrhagic fever virus: A narrative review. Travel Med. Infect. Dis. 37, 101871 (2020).
Google Scholar
Vorou, R., Pierroutsakos, I. N. & Maltezou, H. C. Crimean-Congo hemorrhagic fever. Curr. Opin. Infect. Dis. 20, 495–500 (2007).
Google Scholar
Shayan, S., Bokaean, M., Shahrivar, M. R. & Chinikar, S. Crimean-Congo Hemorrhagic Fever. Lab. Med. 46, 180–189 (2015).
Google Scholar
Dokuzoguz, B. et al. Severity scoring index for Crimean-Congo hemorrhagic fever and the impact of ribavirin and corticosteroids on fatality. Clin. Infect. Dis. 57, 1270–1274 (2013).
Google Scholar
Cevik, M. A. et al. Clinical and laboratory features of Crimean-Congo hemorrhagic fever: predictors of fatality. Int J. Infect. Dis. 12, 374–379 (2008).
Google Scholar
Xu, Z. S. et al. LDLR is an entry receptor for Crimean-Congo hemorrhagic fever virus. Cell Res. 34, 140–150 (2024).
Google Scholar
Freiberg, A. N. et al. Three-dimensional organization of Rift Valley fever virus revealed by cryoelectron tomography. J. Virol. 82, 10341–10348 (2008).
Google Scholar
Nair, N., Osterhaus, A., Rimmelzwaan, G. F. & Prajeeth, C. K. Rift Valley Fever Virus-Infection, Pathogenesis and Host Immune Responses. Pathogens 12, 1174 (2023).
Google Scholar
Halldorsson, S. et al. Shielding and activation of a viral membrane fusion protein. Nat. Commun. 9, 349 (2018).
Google Scholar
Himeidan, Y. E. et al. Recent outbreaks of rift valley Fever in East Africa and the middle East. Front. Public Health 2, 169 (2014).
Google Scholar
Gerken, K. N. et al. Paving the way for human vaccination against Rift Valley fever virus: A systematic literature review of RVFV epidemiology from 1999 to 2021. PLoS Negl. Trop. Dis. 16, e0009852 (2022).
Google Scholar
Seufi, A. M. & Galal, F. H. Role of Culex and Anopheles mosquito species as potential vectors of rift valley fever virus in Sudan outbreak, 2007. BMC Infect. Dis. 10, 65 (2010).
Google Scholar
Odendaal, L., Davis, A. S. & Venter, E. H. Insights into the Pathogenesis of Viral Haemorrhagic Fever Based on Virus Tropism and Tissue Lesions of Natural Rift Valley Fever. Viruses 13, 709 (2021).
Google Scholar
Odendaal, L., Davis, A. S., Fosgate, G. T. & Clift, S. J. Lesions and Cellular Tropism of Natural Rift Valley Fever Virus Infection in Young Lambs. Vet. Pathol. 57, 66–81 (2020).
Google Scholar
Sheehan, K. C. et al. Blocking monoclonal antibodies specific for mouse IFN-alpha/beta receptor subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic transfection. J. Interferon Cytokine Res. 26, 804–819 (2006).
Google Scholar
Garrison, A. R. et al. A DNA vaccine for Crimean-Congo hemorrhagic fever protects against disease and death in two lethal mouse models. PLoS Negl. Trop. Dis. 11, e0005908 (2017).
Google Scholar
Lindquist, M. E. et al. Exploring Crimean-Congo Hemorrhagic Fever Virus-Induced Hepatic Injury Using Antibody-Mediated Type I Interferon Blockade in Mice. J. Virol. 92, e01083–01018 (2018).
Google Scholar
Spengler, J. R. et al. Crimean-Congo Hemorrhagic Fever in Humanized Mice Reveals Glial Cells as Primary Targets of Neurological Infection. J. Infect. Dis. 216, 1386–1397 (2017).
Google Scholar
Hawman, D. W. et al. Immunocompetent mouse model for Crimean-Congo hemorrhagic fever virus. Elife 8, e63906 (2021).
Google Scholar
Fagbami, A. H., Tomori, O., Fabiyi, A. & Isoun, T. T. Experimantal Congo virus (Ib -AN 7620) infection in primates. Virologie 26, 33–37, (1975).
Google Scholar
Smith, D. R. et al. Persistent Crimean-Congo hemorrhagic fever virus infection in the testes and within granulomas of non-human primates with latent tuberculosis. PLoS Pathog. 15, e1008050 (2019).
Google Scholar
Arnold, C. E. et al. Host response transcriptomic analysis of Crimean-Congo hemorrhagic fever pathogenesis in the cynomolgus macaque model. Sci. Rep. 11, 19807 (2021).
Google Scholar
Smith, D. R. et al. The pathogenesis of Rift Valley fever virus in the mouse model. Virology 407, 256–267 (2010).
Google Scholar
Mandell, R. B. et al. A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge. Virology 397, 187–198 (2010).
Google Scholar
Näslund, J. et al. Kinetics of Rift Valley Fever Virus in experimentally infected mice using quantitative real-time RT-PCR. J. Virol. Methods 151, 277–282 (2008).
Google Scholar
van Velden, D. J. et al. Rift Valley fever affecting humans in South Africa: a clinicopathological study. S Afr. Med. J. 51, 867–871 (1977).
Google Scholar
Morrill, J. C. et al. Rapid accumulation of virulent rift valley Fever virus in mice from an attenuated virus carrying a single nucleotide substitution in the m RNA. PLoS One 5, e9986 (2010).
Google Scholar
Anderson, A. O., Snyder, L. F., Pitt, M. L. & Wood, O. L. Mucosal priming alters pathogenesis of Rift Valley fever. Adv. Exp. Med. Biol. 237, 717–723 (1988).
Google Scholar
Anderson, G. W. Jr., Slone, T. W. Jr. & Peters, C. J. The gerbil, Meriones unguiculatus, a model for Rift Valley fever viral encephalitis. Arch. Virol. 102, 187–196 (1988).
Google Scholar
Anderson, G. W. Jr. & Peters, C. J. Viral determinants of virulence for Rift Valley fever (RVF) in rats. Micro. Pathog. 5, 241–250 (1988).
Google Scholar
Anderson, G. W. Jr. et al. Efficacy of a Rift Valley fever virus vaccine against an aerosol infection in rats. Vaccine 9, 710–714 (1991).
Google Scholar
Peters, C. J. & Slone, T. W. Inbred rat strains mimic the disparate human response to Rift Valley fever virus infection. J. Med. Virol. 10, 45–54 (1982).
Google Scholar
Bird, B. H. et al. Rift valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals. J. Virol. 82, 2681–2691 (2008).
Google Scholar
Bales, J. M. et al. Choice of inbred rat strain impacts lethality and disease course after respiratory infection with Rift Valley Fever Virus. Front. Cell Infect. Microbiol 2, 105 (2012).
Google Scholar
Ikegami, T. & Makino, S. The pathogenesis of Rift Valley fever. Viruses 3, 493–519 (2011).
Google Scholar
Niklasson, B. S., Meadors, G. F. & Peters, C. J. Active and passive immunization against Rift Valley fever virus infection in Syrian hamsters. Acta Pathol. Microbiol. Immunol. Scand. C 92, 197–200 (1984).
Google Scholar
Westover, J. B. et al. Galidesivir limits Rift Valley fever virus infection and disease in Syrian golden hamsters. Antivir. Res 156, 38–45 (2018).
Google Scholar
Sall, A. A. et al. Genetic reassortment of Rift Valley fever virus in nature. J. Virol. 73, 8196–8200 (1999).
Google Scholar
Ross, T. M. et al. Animal models of Rift Valley fever virus infection. Virus Res. 163, 417–423 (2012).
Google Scholar
Pavel, S. T. I., Yetiskin, H., Kalkan, A. & Ozdarendeli, A. Evaluation of the cell culture based and the mouse brain derived inactivated vaccines against Crimean-Congo hemorrhagic fever virus in transiently immune-suppressed (IS) mouse model. PLoS Negl. Trop. Dis. 14, e0008834 (2020).
Google Scholar
Kortekaas, J. et al. Crimean-Congo Hemorrhagic Fever Virus Subunit Vaccines Induce High Levels of Neutralizing Antibodies But No Protection in STAT1 Knockout Mice. Vector Borne Zoonotic Dis. 15, 759–764 (2015).
Google Scholar
Scholte, F. E. M. et al. Single-dose replicon particle vaccine provides complete protection against Crimean-Congo hemorrhagic fever virus in mice. Emerg. Microbes Infect. 8, 575–578 (2019).
Google Scholar
Hinkula, J. et al. Immunization with DNA Plasmids Coding for Crimean-Congo Hemorrhagic Fever Virus Capsid and Envelope Proteins and/or Virus-Like Particles Induces Protection and Survival in Challenged Mice. J. Virol. 91, e02076–16 (2017).
Google Scholar
Buttigieg, K. R. et al. A novel vaccine against Crimean-Congo Haemorrhagic Fever protects 100% of animals against lethal challenge in a mouse model. PloS One 9, e91516 (2014).
Google Scholar
Zivcec, M. et al. Nucleocapsid protein-based vaccine provides protection in mice against lethal Crimean-Congo hemorrhagic fever virus challenge. PLoS Neglected Tropical Dis. 12, e0006628 (2018).
Google Scholar
Rodriguez, S. E. et al. Vesicular Stomatitis Virus-Based Vaccine Protects Mice against Crimean-Congo Hemorrhagic Fever. Sci. Rep. 9, 7755 (2019).
Google Scholar
Faburay, B. et al. Current Status of Rift Valley Fever Vaccine Development. Vaccines 5, 29 (2017).
Google Scholar
Randall, R. et al. The development of a formalin-killed Rift Valley fever virus vaccine for use in man. J. Immunol. 89, 660–671 (1962).
Google Scholar
Sindato, C. et al. Safety, Immunogenicity and Antibody Persistence of Rift Valley Fever Virus Clone 13 Vaccine in Sheep, Goats and Cattle in Tanzania. Front. Vet. Sci. 8, 779858 (2021).
Google Scholar
Faburay, B. et al. A glycoprotein subunit vaccine elicits a strong Rift Valley fever virus neutralizing antibody response in sheep. Vector Borne Zoonotic Dis. 14, 746–756 (2014).
Google Scholar
Faburay, B. et al. A Recombinant Rift Valley Fever Virus Glycoprotein Subunit Vaccine Confers Full Protection against Rift Valley Fever Challenge in Sheep. Sci. Rep. 6, 27719 (2016).
Google Scholar
Appelberg, S. et al. Nucleoside-Modified mRNA Vaccines Protect IFNAR(−/−) Mice against Crimean-Congo Hemorrhagic Fever Virus Infection. J. Virol. 96, e0156821 (2022).
Google Scholar
de Boer, S. M. et al. Rift Valley fever virus subunit vaccines confer complete protection against a lethal virus challenge. Vaccine 28, 2330–2339 (2010).
Google Scholar
Suschak, J. J. et al. A CCHFV DNA vaccine protects against heterologous challenge and establishes GP38 as immunorelevant in mice. NPJ Vaccines 6, 31 (2021).
Google Scholar
Hawman, D. W. et al. A DNA-based vaccine protects against Crimean-Congo haemorrhagic fever virus disease in a Cynomolgus macaque model. Nat. Microbiol. 6, 187–195 (2021).
Google Scholar
Tipih, T., Heise, M. & Burt, F. J. Immunogenicity of a DNA-Based Sindbis Replicon Expressing Crimean-Congo Hemorrhagic Fever Virus Nucleoprotein. Vaccines 9, 1491 (2021).
Google Scholar
Holman, D. H. et al. A complex adenovirus-vectored vaccine against Rift Valley fever virus protects mice against lethal infection in the presence of preexisting vector immunity. Clin. Vaccin. Immunol. 16, 1624–1632 (2009).
Google Scholar
Spik, K. et al. Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus. Vaccine 24, 4657–4666 (2006).
Google Scholar
Dowall, S. D. et al. A Crimean-Congo hemorrhagic fever (CCHF) viral vaccine expressing nucleoprotein is immunogenic but fails to confer protection against lethal disease. Hum. Vaccin. Immunother. 12, 519–527 (2016).
Google Scholar
Leventhal, S. S. et al. Replicating RNA vaccination elicits an unexpected immune response that efficiently protects mice against lethal Crimean-Congo hemorrhagic fever virus challenge. EBioMedicine 82, 104188 (2022).
Google Scholar
Elaldi, N. et al. Efficacy of oral ribavirin treatment in Crimean-Congo haemorrhagic fever: a quasi-experimental study from Turkey. J. Infect. 58, 238–244 (2009).
Google Scholar
Oestereich, L. et al. Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever. PLoS Neglected Tropical Dis. 8, e2804 (2014).
Google Scholar
Hawman, D. W. et al. Favipiravir (T-705) but not ribavirin is effective against two distinct strains of Crimean-Congo hemorrhagic fever virus in mice. Antivir. Res. 157, 18–26 (2018).
Google Scholar
Wang, Q. et al. In vitro and in vivo efficacy of a novel nucleoside analog H44 against Crimean-Congo hemorrhagic fever virus. Antivir. Res. 199, 105273 (2022).
Google Scholar
Hawman, D. W. et al. Efficacy of favipiravir (T-705) against Crimean-Congo hemorrhagic fever virus infection in cynomolgus macaques. Antivir. Res. 181, 104858 (2020).
Google Scholar
Welch, S. R. et al. Identification of 2’-deoxy-2’-fluorocytidine as a potent inhibitor of Crimean-Congo hemorrhagic fever virus replication using a recombinant fluorescent reporter virus. Antivir. Res. 147, 91–99 (2017).
Google Scholar
Suleiman, M. N. et al. Congo/Crimean haemorrhagic fever in Dubai. An outbreak at the Rashid Hospital. Lancet 2, 939–941 (1980).
Google Scholar
Vassilenko, S. M. et al. Specific intravenous immunoglobulin for Crimean-Congo haemorrhagic fever. Lancet 335, 791–792 (1990).
Google Scholar
Bertolotti-Ciarlet, A. et al. Cellular localization and antigenic characterization of crimean-congo hemorrhagic fever virus glycoproteins. J. Virol. 79, 6152–6161 (2005).
Google Scholar
Golden, J. W. et al. GP38-targeting monoclonal antibodies protect adult mice against lethal Crimean-Congo hemorrhagic fever virus infection. Sci. Adv. 5, eaaw9535 (2019).
Google Scholar
Mishra, A. K. et al. Structure and Characterization of Crimean-Congo Hemorrhagic Fever Virus GP38. J. Virol. 94, e02005–e02019 (2020).
Google Scholar
Fels, J. M. et al. Protective neutralizing antibodies from human survivors of Crimean-Congo hemorrhagic fever. Cell 184, 3486–3501.e3421 (2021).
Google Scholar
Mishra, A. K. et al. Structural basis of synergistic neutralization of Crimean-Congo hemorrhagic fever virus by human antibodies. Science 375, 104–109 (2022).
Google Scholar
Allen, E. R. et al. A Protective Monoclonal Antibody Targets a Site of Vulnerability on the Surface of Rift Valley Fever Virus. Cell Rep. 25, 3750–3758.e3754 (2018).
Google Scholar
Hao, M. et al. Characterization of Two Neutralizing Antibodies against Rift Valley Fever Virus Gn Protein. Viruses 12, 259 (2020).
Google Scholar
McMillen, C. M. et al. A highly potent human neutralizing antibody prevents vertical transmission of Rift Valley fever virus in a rat model. Nat. Commun. 14, 4507 (2023).
Google Scholar
Gutjahr, B. et al. Two monoclonal antibodies against glycoprotein Gn protect mice from Rift Valley Fever challenge by cooperative effects. PLoS Negl. Trop. Dis. 14, e0008143 (2020).
Google Scholar
Chapman, N. S. et al. Multifunctional human monoclonal antibody combination mediates protection against Rift Valley fever virus at low doses. Nat. Commun. 14, 5650 (2023).
Google Scholar
Chapman, N. S. et al. Potent neutralization of Rift Valley fever virus by human monoclonal antibodies through fusion inhibition. Proc. Natl Acad. Sci. USA 118, e2025642118 (2021).
Google Scholar
Wang, Q. et al. Neutralization mechanism of human monoclonal antibodies against Rift Valley fever virus. Nat. Microbiol. 4, 1231–1241 (2019).
Google Scholar
Cartwright, H. N., Barbeau, D. J. & McElroy, A. K. Isotype-Specific Fc Effector Functions Enhance Antibody-Mediated Rift Valley Fever Virus Protection In Vivo. mSphere 6, e0055621 (2021).
Google Scholar
Zhao, Y. et al. Equine immunoglobulin F(ab’)(2) fragments protect mice from Rift Valley fever virus infection. Int. Immunopharmacol. 64, 217–222 (2018).
Google Scholar
Wichgers Schreur, P. J. et al. Multimeric single-domain antibody complexes protect against bunyavirus infections. eLife 9, e52716 (2020).
Google Scholar
Eaton, B. T., Broder, C. C., Middleton, D. & Wang, L. F. Hendra and Nipah viruses: different and dangerous. Nat. Rev. Microbiol. 4, 23–35 (2006).
Google Scholar
Ternhag, A. & Penttinen, P. [Nipah virus–another product from the Asian “virus factory”]. Lakartidningen 102, 1046–1047 (2005).
Google Scholar
Ciancanelli, M. J. & Basler, C. F. Mutation of YMYL in the Nipah virus matrix protein abrogates budding and alters subcellular localization. J. Virol. 80, 12070–12078 (2006).
Google Scholar
Chua, K. B. Nipah virus outbreak in Malaysia. J. Clin. Virol. 26, 265–275 (2003).
Google Scholar
Chua, K. B. et al. Nipah virus: a recently emergent deadly paramyxovirus. Science 288, 1432–1435 (2000).
Google Scholar
Gazal, S. et al. Nipah and Hendra Viruses: Deadly Zoonotic Paramyxoviruses with the Potential to Cause the Next Pandemic. Pathogens 11, 1419 (2022).
Google Scholar
Wong, K. T. et al. Nipah virus infection: pathology and pathogenesis of an emerging paramyxoviral zoonosis. Am. J. Pathol. 161, 2153–2167 (2002).
Google Scholar
Gurley, E. S. et al. Person-to-person transmission of Nipah virus in a Bangladeshi community. Emerg. Infect. Dis. 13, 1031–1037 (2007).
Google Scholar
Sun, B. et al. Phylogeography, Transmission, and Viral Proteins of Nipah Virus. Virol. Sin. 33, 385–393 (2018).
Google Scholar
Rockx, B. et al. Clinical outcome of henipavirus infection in hamsters is determined by the route and dose of infection. J. Virol. 85, 7658–7671 (2011).
Google Scholar
Kaza, B. & Aguilar, H. C. Pathogenicity and virulence of henipaviruses. Virulence 14, 2273684 (2023).
Google Scholar
Singh, R. K. et al. Nipah virus: epidemiology, pathology, immunobiology and advances in diagnosis, vaccine designing and control strategies – a comprehensive review. Vet. Q. 39, 26–55 (2019).
Google Scholar
Broder, C. C. et al. A treatment for and vaccine against the deadly Hendra and Nipah viruses. Antivir. Res. 100, 8–13 (2013).
Google Scholar
Dhondt, K. P. et al. Type I interferon signaling protects mice from lethal henipavirus infection. J. Infect. Dis. 207, 142–151 (2013).
Google Scholar
Iampietro, M. et al. Activation of cGAS/STING pathway upon paramyxovirus infection. iScience 24, 102519 (2021).
Google Scholar
Iampietro, M. et al. Control of Nipah Virus Infection in Mice by the Host Adaptors Mitochondrial Antiviral Signaling Protein (MAVS) and Myeloid Differentiation Primary Response 88 (MyD88). J. Infect. Dis. 221, S401–s406 (2020).
Google Scholar
Valbuena, G. et al. A human lung xenograft mouse model of Nipah virus infection. PLoS Pathog. 10, e1004063 (2014).
Google Scholar
Walpita, P. et al. A VLP-based vaccine provides complete protection against Nipah virus challenge following multiple-dose or single-dose vaccination schedules in a hamster model. NPJ Vaccines 2, 21 (2017).
Google Scholar
Welch, S. R. et al. Defective Interfering Viral Particle Treatment Reduces Clinical Signs and Protects Hamsters from Lethal Nipah Virus Disease. mBio 13, e0329421 (2022).
Google Scholar
Wong, K. T. et al. A golden hamster model for human acute Nipah virus infection. Am. J. Pathol. 163, 2127–2137 (2003).
Google Scholar
Welch, S. R. et al. In Situ Imaging of Fluorescent Nipah Virus Respiratory and Neurological Tissue Tropism in the Syrian Hamster Model. J. Infect. Dis. 221, S448–s453 (2020).
Google Scholar
Williamson, M. M. & Torres-Velez, F. J. Henipavirus: a review of laboratory animal pathology. Vet. Pathol. 47, 871–880 (2010).
Google Scholar
Torres-Velez, F. J. et al. Histopathologic and immunohistochemical characterization of Nipah virus infection in the guinea pig. Vet. Pathol. 45, 576–585 (2008).
Google Scholar
Genzer, S. C. et al. Alterations in Blood Chemistry Levels Associated With Nipah Virus Disease in the Syrian Hamster Model. J. Infect. Dis. 221, S454–s459 (2020).
Google Scholar
Clayton, B. A. et al. The Nature of Exposure Drives Transmission of Nipah Viruses from Malaysia and Bangladesh in Ferrets. PLoS Negl. Trop. Dis. 10, e0004775 (2016).
Google Scholar
Pickering, B. S. et al. Protection against henipaviruses in swine requires both, cell-mediated and humoral immune response. Vaccine 34, 4777–4786 (2016).
Google Scholar
Mills, J. N. et al. Nipah virus infection in dogs, Malaysia, 1999. Emerg. Infect. Dis. 15, 950–952 (2009).
Google Scholar
Middleton, D. J. et al. Experimental Nipah virus infection in pigs and cats. J. Comp. Pathol. 126, 124–136 (2002).
Google Scholar
Mungall, B. A. et al. Vertical transmission and fetal replication of Nipah virus in an experimentally infected cat. J. Infect. Dis. 196, 812–816 (2007).
Google Scholar
Geisbert, T. W. et al. Development of an acute and highly pathogenic nonhuman primate model of Nipah virus infection. PloS One 5, e10690 (2010).
Google Scholar
Geisbert, J. B. et al. An Intranasal Exposure Model of Lethal Nipah Virus Infection in African Green Monkeys. J. Infect. Dis. 221, S414–s418 (2020).
Google Scholar
Prasad, A. N. et al. A Lethal Aerosol Exposure Model of Nipah Virus Strain Bangladesh in African Green Monkeys. J. Infect. Dis. 221, S431–s435 (2020).
Google Scholar
Geisbert, T. W., Feldmann, H. & Broder, C. C. Animal challenge models of henipavirus infection and pathogenesis. Curr. Top. Microbiol. Immunol. 359, 153–177 (2012).
Google Scholar
Mire, C. E. et al. Pathogenic Differences between Nipah Virus Bangladesh and Malaysia Strains in Primates: Implications for Antibody Therapy. Sci. Rep. 6, 30916 (2016).
Google Scholar
Prasad, A. N. et al. Resistance of Cynomolgus Monkeys to Nipah and Hendra Virus Disease Is Associated With Cell-Mediated and Humoral Immunity. J. Infect. Dis. 221, S436–s447 (2020).
Google Scholar
Marianneau, P. et al. Experimental infection of squirrel monkeys with nipah virus. Emerg. Infect. Dis. 16, 507–510 (2010).
Google Scholar
Mire, C. E. et al. Single injection recombinant vesicular stomatitis virus vaccines protect ferrets against lethal Nipah virus disease. Virol. J. 10, 353 (2013).
Google Scholar
Watanabe, S. et al. Construction of a recombinant vaccine expressing Nipah virus glycoprotein using the replicative and highly attenuated vaccinia virus strain LC16m8. PLoS Negl. Trop. Dis. 17, e0011851 (2023).
Google Scholar
Walpita, P. et al. Vaccine potential of Nipah virus-like particles. PloS one 6, e18437 (2011).
Google Scholar
Pastor, Y. et al. A vaccine targeting antigen-presenting cells through CD40 induces protective immunity against Nipah disease. Cell Rep. Med. 5, 101467 (2024).
Google Scholar
Porotto, M. et al. Inhibition of Nipah virus infection in vivo: targeting an early stage of paramyxovirus fusion activation during viral entry. PLoS Pathog. 6, e1001168 (2010).
Google Scholar
Dawes, B. E. et al. Favipiravir (T-705) protects against Nipah virus infection in the hamster model. Sci. Rep. 8, 7604 (2018).
Google Scholar
Rodrigue, V. et al. Current progress towards prevention of Nipah and Hendra disease in humans: A scoping review of vaccine and monoclonal antibody candidates being evaluated in clinical trials. Trop. Med. Int. Health 29, 354–364 (2024).
Google Scholar
Bossart, K. N. et al. A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection. PLoS Pathog. 5, e1000642 (2009).
Google Scholar
Geisbert, T. W. et al. Therapeutic treatment of Nipah virus infection in nonhuman primates with a neutralizing human monoclonal antibody. Sci. Transl. Med. 6, 242ra282 (2014).
Google Scholar
Playford, E. G. et al. Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody targeting the G glycoprotein of henipaviruses in healthy adults: a first-in-human, randomised, controlled, phase 1 study. Lancet Infect. Dis. 20, 445–454 (2020).
Google Scholar
Chen, L. et al. Potent human neutralizing antibodies against Nipah virus derived from two ancestral antibody heavy chains. Nat. Commun. 15, 2987 (2024).
Google Scholar
Mathieu, C. & Horvat, B. Henipavirus pathogenesis and antiviral approaches. Expert Rev. Anti Infect. Ther. 13, 343–354 (2015).
Google Scholar
Sharma, V. et al. Zika virus: an emerging challenge to public health worldwide. Can. J. Microbiol. 66, 87–98 (2020).
Google Scholar
Roby, J. A., Setoh, Y. X., Hall, R. A. & Khromykh, A. A. Post-translational regulation and modifications of flavivirus structural proteins. J. Gen. Virol. 96, 1551–1569 (2015).
Google Scholar
Mukhopadhyay, S., Kuhn, R. J. & Rossmann, M. G. A structural perspective of the flavivirus life cycle. Nat. Rev. Microbiol. 3, 13–22 (2005).
Google Scholar
Klema, V. J., Padmanabhan, R. & Choi, K. H. Flaviviral Replication Complex: Coordination between RNA Synthesis and 5’-RNA Capping. Viruses 7, 4640–4656 (2015).
Google Scholar
van den Elsen, K., Quek, J. P. & Luo, D. Molecular Insights into the Flavivirus Replication Complex. Viruses 13, 956 (2021).
Google Scholar
Liang, Q. et al. Zika Virus NS4A and NS4B Proteins Deregulate Akt-mTOR Signaling in Human Fetal Neural Stem Cells to Inhibit Neurogenesis and Induce Autophagy. Cell Stem Cell 19, 663–671 (2016).
Google Scholar
Franke, T. F. PI3K/Akt: getting it right matters. Oncogene 27, 6473–6488 (2008).
Google Scholar
Parisien, J.-P., Lenoir, J. J., Alvarado, G. & Horvath, C. M. The Human STAT2 Coiled-Coil Domain Contains a Degron for Zika Virus Interferon Evasion. J. Virol. 96, e0130121 (2022).
Google Scholar
Xia, H. et al. An evolutionary NS1 mutation enhances Zika virus evasion of host interferon induction. Nat. Commun. 9, 414 (2018).
Google Scholar
Wu, Y. et al. Zika virus evades interferon-mediated antiviral response through the co-operation of multiple nonstructural proteins in vitro. Cell Discov. 3, 17006 (2017).
Google Scholar
Zeng, Q. et al. Making sense of flavivirus non-strctural protein 1 in innate immune evasion and inducing tissue-specific damage. Virus Res. 336, 199222 (2023).
Google Scholar
Perera, D. R., Ranadeva, N. D., Sirisena, K. & Wijesinghe, K. J. Roles of NS1 Protein in Flavivirus Pathogenesis. ACS Infect. Dis. 10, 20–56 (2024).
Google Scholar
Wu, L. et al. An evolutionarily conserved ubiquitin ligase drives infection and transmission of flaviviruses. Proc. Natl Acad. Sci. USA 121, e2317978121 (2024).
Google Scholar
Petersen, L. R., Jamieson, D. J. & Honein, M. A. Zika Virus. N. Engl. J. Med. 375, 294–295 (2016).
Google Scholar
Hills, S. L., Fischer, M. & Petersen, L. R. Epidemiology of Zika Virus Infection. J. Infect. Dis. 216, S868–S874 (2017).
Google Scholar
Sekaran, S. D. et al. Host immune response against DENV and ZIKV infections. Front Cell Infect. Microbiol 12, 975222 (2022).
Google Scholar
Besnard, M. et al. Evidence of perinatal transmission of Zika virus, French Polynesia, December 2013 and February 2014. Eur. Surveill. 19, 20751 (2014).
Google Scholar
Russell, K. et al. Male-to-Female Sexual Transmission of Zika Virus-United States, January-April 2016. Clin. Infect. Dis. 64, 211–213 (2017).
Google Scholar
Leyser, M. & Nascimento, O. J. M. Congenital Zika Virus Infection: Beyond Neonatal Microcephaly. JAMA Neurol. 74, 610 (2017).
Google Scholar
Giraldo, M. I., Gonzalez-Orozco, M. & Rajsbaum, R. Pathogenesis of Zika Virus Infection. Annu Rev. Pathol. 18, 181–203 (2023).
Google Scholar
Lazear, H. M. et al. A Mouse Model of Zika Virus Pathogenesis. Cell Host Microbe 19, 720–730 (2016).
Google Scholar
Rossi, S. L. et al. Characterization of a Novel Murine Model to Study Zika Virus. Am. J. Trop. Med. Hyg. 94, 1362–1369 (2016).
Google Scholar
Grant, A. et al. Zika Virus Targets Human STAT2 to Inhibit Type I Interferon Signaling. Cell Host Microbe 19, 882–890 (2016).
Google Scholar
Kumar, A. et al. Zika virus inhibits type-I interferon production and downstream signaling. EMBO Rep. 17, 1766–1775 (2016).
Google Scholar
Fernandes, N. C. et al. Experimental Zika virus infection induces spinal cord injury and encephalitis in newborn Swiss mice. Exp. Toxicol. Pathol. 69, 63–71 (2017).
Google Scholar
Manangeeswaran, M., Ireland, D. D. & Verthelyi, D. Zika (PRVABC59) Infection Is Associated with T cell Infiltration and Neurodegeneration in CNS of Immunocompetent Neonatal C57Bl/6 Mice. PLoS Pathog. 12, e1006004 (2016).
Google Scholar
Li, S. et al. Zika Virus Fatally Infects Wild Type Neonatal Mice and Replicates in Central Nervous System. Viruses 10, 49 (2018).
Google Scholar
Dowall, S. D. et al. A Susceptible Mouse Model for Zika Virus Infection. PLoS Negl. Trop. Dis. 10, e0004658 (2016).
Google Scholar
Li, H. et al. Zika Virus Infects Neural Progenitors in the Adult Mouse Brain and Alters Proliferation. Cell Stem Cell 19, 593–598 (2016).
Google Scholar
Smith, D. R. et al. Neuropathogenesis of Zika Virus in a Highly Susceptible Immunocompetent Mouse Model after Antibody Blockade of Type I Interferon. PLoS Negl. Trop. Dis. 11, e0005296 (2017).
Google Scholar
Aliota, M. T. et al. Characterization of Lethal Zika Virus Infection in AG129 Mice. PLoS Negl. Trop. Dis. 10, e0004682 (2016).
Google Scholar
Govero, J. et al. Zika virus infection damages the testes in mice. Nature 540, 438–442 (2016).
Google Scholar
Ma, W. et al. Zika Virus Causes Testis Damage and Leads to Male Infertility in Mice. Cell 168, 542 (2017).
Google Scholar
Chan, J. F. et al. Zika Virus Infection in Dexamethasone-immunosuppressed Mice Demonstrating Disseminated Infection with Multi-organ Involvement Including Orchitis Effectively Treated by Recombinant Type I Interferons. EBioMedicine 14, 112–122 (2016).
Google Scholar
Schuler-Faccini, L. et al. Possible Association Between Zika Virus Infection and Microcephaly – Brazil, 2015. MMWR Morb. Mortal. Wkly Rep. 65, 59–62 (2016).
Google Scholar
Duarte, G. et al. Zika Virus Infection in Pregnant Women and Microcephaly. Rev. Bras. Ginecol. Obstet. 39, 235–248 (2017).
Google Scholar
Miner, J. J. et al. Zika Virus Infection during Pregnancy in Mice Causes Placental Damage and Fetal Demise. Cell 165, 1081–1091 (2016).
Google Scholar
Cugola, F. R. et al. The Brazilian Zika virus strain causes birth defects in experimental models. Nature 534, 267–271 (2016).
Google Scholar
Siddharthan, V. et al. Zika virus infection of adult and fetal STAT2 knock-out hamsters. Virology 507, 89–95 (2017).
Google Scholar
Miller, L. J. et al. Zika Virus Infection in Syrian Golden Hamsters and Strain 13 Guinea Pigs. Am. J. Trop. Med Hyg. 98, 864–867 (2018).
Google Scholar
Deng, Y.-Q. et al. Intranasal infection and contact transmission of Zika virus in guinea pigs. Nat. Commun. 8, 1648 (2017).
Google Scholar
Bierle, C. J. et al. Assessing Zika virus replication and the development of Zika-specific antibodies after a mid-gestation viral challenge in guinea pigs. PLoS One 12, e0187720 (2017).
Google Scholar
Kumar, M. et al. A guinea pig model of Zika virus infection. Virol. J. 14, 75 (2017).
Google Scholar
Qiu, H.-Y. et al. Aerosolized Zika virus infection in Guinea pigs. Emerg. Microbes Infect. 11, 2350–2358 (2022).
Google Scholar
Westrich, J. A. et al. Characterization of subclinical ZIKV infection in immune-competent guinea pigs and mice. J. Gen. Virol. 102, 001641 (2021).
Google Scholar
Hutchinson, E. B. et al. The effect of Zika virus infection in the ferret. J. Comp. Neurol. 527, 1706–1719 (2019).
Google Scholar
Dudley, D. M. et al. A rhesus macaque model of Asian-lineage Zika virus infection. Nat. Commun. 7, 12204 (2016).
Google Scholar
Koenig, M. R. et al. Infection of the maternal-fetal interface and vertical transmission following low-dose inoculation of pregnant rhesus macaques (Macaca mulatta) with an African-lineage Zika virus. PLoS One 18, e0284964 (2023).
Google Scholar
Aid, M. et al. Zika Virus Persistence in the Central Nervous System and Lymph Nodes of Rhesus Monkeys. Cell 169, 610–620.e14 (2017).
Google Scholar
Hirsch, A. J. et al. Zika Virus infection of rhesus macaques leads to viral persistence in multiple tissues. PLoS Pathog. 13, e1006219 (2017).
Google Scholar
Osuna, C. E. et al. Zika viral dynamics and shedding in rhesus and cynomolgus macaques. Nat. Med. 22, 1448–1455 (2016).
Google Scholar
Li, X.-F. et al. Characterization of a 2016 Clinical Isolate of Zika Virus in Non-human Primates. EBioMedicine 12, 170–177 (2016).
Google Scholar
Woollard, S. M. et al. Preliminary Studies on Immune Response and Viral Pathogenesis of Zika Virus in Rhesus Macaques. Pathogens 7, 70 (2018).
Google Scholar
Rosinski, J. R. et al. Frequent first-trimester pregnancy loss in rhesus macaques infected with African-lineage Zika virus. PLoS Pathog. 19, e1011282 (2023).
Google Scholar
Raasch, L. E. et al. Fetal loss in pregnant rhesus macaques infected with high-dose African-lineage Zika virus. PLoS Negl. Trop. Dis. 16, e0010623 (2022).
Google Scholar
Block, L. N. et al. Embryotoxic impact of Zika virus in a rhesus macaque in vitro implantation model†. Biol. Reprod. 102, 806–816 (2020).
Google Scholar
Steinbach, R. J. et al. A neonatal nonhuman primate model of gestational Zika virus infection with evidence of microencephaly, seizures and cardiomyopathy. PLoS One 15, e0227676 (2020).
Google Scholar
Martinot, A. J. et al. Fetal Neuropathology in Zika Virus-Infected Pregnant Female Rhesus Monkeys. Cell 173, 1111–1122.e10 (2018).
Google Scholar
Beckman, D. et al. Neuroanatomical abnormalities in a nonhuman primate model of congenital Zika virus infection. Elife 11, e64734 (2022).
Google Scholar
Tarantal, A. F. et al. Fetal Rhesus Monkey First Trimester Zika Virus Infection Impacts Cortical Development in the Second and Third Trimesters. Cereb. Cortex 31, 2309–2321 (2021).
Google Scholar
Raper, J. et al. Long-term alterations in brain and behavior after postnatal Zika virus infection in infant macaques. Nat. Commun. 11, 2534 (2020).
Google Scholar
Coffey, L. L. et al. Intraamniotic Zika virus inoculation of pregnant rhesus macaques produces fetal neurologic disease. Nat. Commun. 9, 2414 (2018).
Google Scholar
Mavigner, M. et al. Postnatal Zika virus infection is associated with persistent abnormalities in brain structure, function, and behavior in infant macaques. Sci. Transl. Med. 10, eaao6975 (2018).
Google Scholar
Yiu, G. et al. Evolution of ocular defects in infant macaques following in utero Zika virus infection. JCI Insight 5, e143947 (2020).
Google Scholar
Dudley, D. M. et al. Infection via mosquito bite alters Zika virus tissue tropism and replication kinetics in rhesus macaques. Nat. Commun. 8, 2096 (2017).
Google Scholar
Marlin, R. et al. Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates. Nat. Commun. 13, 5108 (2022).
Google Scholar
Lecouturier, V. et al. An optimized purified inactivated Zika vaccine provides sustained immunogenicity and protection in cynomolgus macaques. NPJ Vaccines 5, 19 (2020).
Google Scholar
Breitbach, M. E. et al. Primary infection with dengue or Zika virus does not affect the severity of heterologous secondary infection in macaques. PLoS Pathog. 15, e1007766 (2019).
Google Scholar
de Alwis, R. et al. Systemic inflammation, innate immunity and pathogenesis after Zika virus infection in cynomolgus macaques are modulated by strain-specificity within the Asian lineage. Emerg. Microbes Infect. 10, 1457–1470 (2021).
Google Scholar
Azar, S. R. et al. ZIKV Demonstrates Minimal Pathologic Effects and Mosquito Infectivity in Viremic Cynomolgus Macaques. Viruses 10, 661 (2018).
Google Scholar
Koide, F. et al. Development of a Zika Virus Infection Model in Cynomolgus Macaques. Front. Microbiol. 7, 2028 (2016).
Google Scholar
Berry, N. et al. Mucosal Responses to Zika Virus Infection in Cynomolgus Macaques. Pathogens 11, 1033 (2022).
Google Scholar
Haddow, A. D. et al. High Infection Rates for Adult Macaques after Intravaginal or Intrarectal Inoculation with Zika Virus. Emerg. Infect. Dis. 23, 1274–1281 (2017).
Google Scholar
Shofa, M. et al. Repeated Intravaginal Inoculation of Zika Virus Protects Cynomolgus Monkeys from Subcutaneous Superchallenge. Int J. Mol. Sci. 23, 14002 (2022).
Google Scholar
Haddow, A. D. et al. Modeling mosquito-borne and sexual transmission of Zika virus in an enzootic host, the African green monkey. PLoS Negl. Trop. Dis. 14, e0008107 (2020).
Google Scholar
O’Connor, M. A. et al. Early cellular innate immune responses drive Zika viral persistence and tissue tropism in pigtail macaques. Nat. Commun. 9, 3371 (2018).
Google Scholar
Adams Waldorf, K. M. et al. Congenital Zika virus infection as a silent pathology with loss of neurogenic output in the fetal brain. Nat. Med. 24, 368–374 (2018).
Google Scholar
Adams Waldorf, K. M. et al. Fetal brain lesions after subcutaneous inoculation of Zika virus in a pregnant nonhuman primate. Nat. Med. 22, 1256–1259 (2016).
Google Scholar
Chiu, C. Y. et al. Experimental Zika Virus Inoculation in a New World Monkey Model Reproduces Key Features of the Human Infection. Sci. Rep. 7, 17126 (2017).
Google Scholar
Lum, F.-M. et al. Multimodal assessments of Zika virus immune pathophysiological responses in marmosets. Sci. Rep. 8, 17125 (2018).
Google Scholar
Berry, N. et al. High susceptibility, viral dynamics and persistence of South American Zika virus in New World monkey species. Sci. Rep. 9, 14495 (2019).
Google Scholar
Seferovic, M. et al. Experimental Zika Virus Infection in the Pregnant Common Marmoset Induces Spontaneous Fetal Loss and Neurodevelopmental Abnormalities. Sci. Rep. 8, 6851 (2018).
Google Scholar
Robbiani, D. F. et al. Risk of Zika microcephaly correlates with features of maternal antibodies. J. Exp. Med. 216, 2302–2315 (2019).
Google Scholar
Gurung, S. et al. Translational Model of Zika Virus Disease in Baboons. J Virol. 92, e00186-18 (2018).
Gurung, S. et al. Zika virus infection at mid-gestation results in fetal cerebral cortical injury and fetal death in the olive baboon. PLoS Pathog. 15, e1007507 (2019).
Google Scholar
Gurung, S. et al. Early and mid-gestation Zika virus (ZIKV) infection in the olive baboon (Papio anubis) leads to fetal CNS pathology by term gestation. PLoS Pathog. 18, e1010386 (2022).
Google Scholar
Peregrine, J. et al. Zika Virus Infection, Reproductive Organ Targeting, and Semen Transmission in the Male Olive Baboon. J. Virol. 94, e01434–19 (2019).
Google Scholar
Modjarrad, K. et al. Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials. Lancet 391, 563–571 (2018).
Google Scholar
Abbink, P. et al. Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science 353, 1129–1132 (2016).
Google Scholar
Muthumani, K. et al. In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine. NPJ Vaccines 1, 16021 (2016).
Google Scholar
Dowd, K. A. et al. Rapid development of a DNA vaccine for Zika virus. Science 354, 237–240 (2016).
Google Scholar
Gaudinski, M. R. et al. Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials. Lancet 391, 552–562 (2018).
Google Scholar
Deering, R. P. et al. Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines. Expert Opin. Drug Deliv. 11, 885–899 (2014).
Google Scholar
Pardi, N. et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature 543, 248–251 (2017).
Google Scholar
Chahal, J. S. et al. An RNA nanoparticle vaccine against Zika virus elicits antibody and CD8+ T cell responses in a mouse model. Sci. Rep. 7, 252 (2017).
Google Scholar
Abbink, P., Stephenson, K. E. & Barouch, D. H. Zika virus vaccines. Nat. Rev. Microbiol 16, 594–600 (2018).
Google Scholar
Combredet, C. et al. A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice. J. Virol. 77, 11546–11554 (2003).
Google Scholar
López-Camacho, C. et al. Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors. Nat. Commun. 9, 2441 (2018).
Google Scholar
Sapparapu, G. et al. Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice. Nature 540, 443–447 (2016).
Google Scholar
Stettler, K. et al. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science 353, 823–826 (2016).
Google Scholar
Barba-Spaeth, G. et al. Structural basis of potent Zika-dengue virus antibody cross-neutralization. Nature 536, 48–53 (2016).
Google Scholar
Zou, J. & Shi, P. Y. Strategies for Zika drug discovery. Curr. Opin. Virol. 35, 19–26 (2019).
Google Scholar
Bernatchez, J. A. et al. Drugs for the Treatment of Zika Virus Infection. J. Med Chem. 63, 470–489 (2020).
Google Scholar
Julander, J. G. et al. Efficacy of the broad-spectrum antiviral compound BCX4430 against Zika virus in cell culture and in a mouse model. Antivir. Res 137, 14–22 (2017).
Google Scholar
Cardoso-Moreira, M. et al. Developmental Gene Expression Differences between Humans and Mammalian Models. Cell Rep. 33, 108308 (2020).
Google Scholar
Wang, S. et al. Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases. Signal Transduct. Target Ther. 8, 149 (2023).
Google Scholar
Li, H. et al. Enhanced protective immunity against SARS-CoV-2 elicited by a VSV vector expressing a chimeric spike protein. Signal Transduct. Target Ther. 6, 389 (2021).
Google Scholar
Vanhoutte, F. et al. Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trial. EBioMedicine 75, 103811 (2022).
Google Scholar
Launay, O. et al. Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study. EBioMedicine 75, 103810 (2022).
Google Scholar
Lloyd-Price, J., Abu-Ali, G. & Huttenhower, C. The healthy human microbiome. Genome Med. 8, 51 (2016).
Google Scholar
Parkin, J. & Cohen, B. An overview of the immune system. Lancet 357, 1777–1789 (2001).
Google Scholar
Liu, G. et al. Clinical Evaluation of Ebola Virus Disease Therapeutics. Trends Mol. Med. 23, 820–830 (2017).
Google Scholar
Gilbert, P. B. et al. A Covid-19 Milestone Attained – A Correlate of Protection for Vaccines. N. Engl. J. Med. 387, 2203–2206 (2022).
Google Scholar
Bray, M. et al. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J. Infect. Dis. 178, 651–661 (1998).
Google Scholar
Arnason, G. The Emergence and Development of Animal Research Ethics: A Review with a Focus on Nonhuman Primates. Sci. Eng. Ethics 26, 2277–2293 (2020).
Google Scholar
Carabelli, A. M. et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat. Rev. Microbiol. 21, 162–177 (2023).
Google Scholar
Deng, W. et al. Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques. Science, 369, 818–823 (2020).
FDA. Animal Rule Summary, < (2017).
McMahan, K. et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature 590, 630–634 (2021).
Google Scholar
Chandrashekar, A. et al. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science 369, 812–817 (2020).
Google Scholar
McKay, P. F. et al. Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice. Nat. Commun. 11, 3523 (2020).
Google Scholar
Earle, K. A. et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 39, 4423–4428 (2021).
Google Scholar
Fong, Y. et al. Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial. Nat. Microbiol. 7, 1996–2010 (2022).
Google Scholar
Weiskopf, D. et al. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. Sci. Immunol. 5, eabd2071 (2020).
Google Scholar
Bradfute, S. B. & Bavari, S. Correlates of immunity to filovirus infection. Viruses 3, 982–1000 (2011).
Google Scholar
Baize, S. et al. Inflammatory responses in Ebola virus-infected patients. Clin. Exp. Immunol. 128, 163–168 (2002).
Google Scholar
Jonkmans, N., D’Acremont, V. & Flahault, A. Scoping future outbreaks: a scoping review on the outbreak prediction of the WHO Blueprint list of priority diseases. BMJ Glob. Health 6, e006623 (2021).
Google Scholar
Rathinam, C. et al. Efficient differentiation and function of human macrophages in humanized CSF-1 mice. Blood 118, 3119–3128 (2011).
Google Scholar
Willinger, T. et al. Human IL-3/GM-CSF knock-in mice support human alveolar macrophage development and human immune responses in the lung. Proc. Natl Acad. Sci. USA 108, 2390–2395 (2011).
Google Scholar
Strowig, T. et al. Transgenic expression of human signal regulatory protein alpha in Rag2−/−gamma(c)−/− mice improves engraftment of human hematopoietic cells in humanized mice. Proc. Natl Acad. Sci. USA 108, 13218–13223 (2011).
Google Scholar
Rongvaux, A. et al. Human thrombopoietin knockin mice efficiently support human hematopoiesis in vivo. Proc. Natl Acad. Sci. USA 108, 2378–2383 (2011).
Google Scholar
Rongvaux, A. et al. Development and function of human innate immune cells in a humanized mouse model. Nat. Biotechnol. 32, 364–372 (2014).
Google Scholar
Yu, H. et al. A novel humanized mouse model with significant improvement of class-switched, antigen-specific antibody production. Blood 129, 959–969 (2017).
Google Scholar
Das, R. et al. Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice. Nat. Med. 22, 1351–1357 (2016).
Google Scholar
Sippel, T. R. et al. Human hematopoietic stem cell maintenance and myeloid cell development in next-generation humanized mouse models. Blood Adv. 3, 268–274 (2019).
Google Scholar
Wahl, A. et al. Precision mouse models with expanded tropism for human pathogens. Nat. Biotechnol. 37, 1163–1173 (2019).
Google Scholar
Kim, H. W. et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89, 422–434 (1969).
Google Scholar
Roy, S. K. & Bhattacharjee, S. Dengue virus: epidemiology, biology, and disease aetiology. Can. J. Microbiol. 67, 687–702 (2021).
Google Scholar
Wan, Y. et al. Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry. J. Virol. 94, e02015–e02019 (2020).
Google Scholar
Takada, A., Feldmann, H., Ksiazek, T. G. & Kawaoka, Y. Antibody-dependent enhancement of Ebola virus infection. J. Virol. 77, 7539–7544 (2003).
Google Scholar
Nakayama, E. et al. Antibody-dependent enhancement of Marburg virus infection. J. Infect. Dis. 204, S978–S985 (2011).
Google Scholar
Kuzmina, N. A. et al. Antibody-Dependent Enhancement of Ebola Virus Infection by Human Antibodies Isolated from Survivors. Cell Rep. 24, 1802–1815.e1805 (2018).
Google Scholar
Jahrling, P. B. et al. Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates. J. Infect. Dis. 196, S400–S403 (2007).
Google Scholar
Oswald, W. B. et al. Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog. 3, e9 (2007).
Google Scholar
Dye, J. M. et al. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc. Natl Acad. Sci. USA 109, 5034–5039 (2012).
Google Scholar
Qiu, X. et al. Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci. Transl. Med. 4, 138ra181 (2012).
Google Scholar
Wang, S. et al. Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys. Nat. Commun. 11, 5752 (2020).
Google Scholar
Zhou, Y. et al. Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD. Cell Rep. 34, 108699 (2021).
Google Scholar
Liu, Y. et al. An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies. Cell 184, 3452–3466.e3418 (2021).
Google Scholar
Li, D. et al. The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates. bioRxiv, (2021).
Bolles, M. et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J. Virol. 85, 12201–12215 (2011).
Google Scholar
Tseng, C. T. et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS One 7, e35421 (2012).
Google Scholar
Munoz, F. M. et al. Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 39, 3053–3066 (2021).
Google Scholar
Bewley, K. R. et al. Immunological and pathological outcomes of SARS-CoV-2 challenge following formalin-inactivated vaccine in ferrets and rhesus macaques. Sci. Adv. 7, eabg7996 (2021).
Google Scholar
Hoffmann, D. et al. CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2. Nat. Commun. 12, 4048 (2021).
Google Scholar
Messaoudi, I., Amarasinghe, G. K. & Basler, C. F. Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus. Nat. Rev. Microbiol. 13, 663–676, (2015).
Google Scholar
Steiner, S. et al. SARS-CoV-2 biology and host interactions. Nat. Rev. Microbiol. 22, 206–225 (2024).
Google Scholar
Zhou, B. et al. SARS-CoV-2 spike D614G change enhances replication and transmission. Nature 592, 122–127 (2021).
Google Scholar
Cool, K. et al. Infection and transmission of ancestral SARS-CoV-2 and its alpha variant in pregnant white-tailed deer. Emerg. Microbes Infect. 11, 95–112 (2022).
Google Scholar
Rathnasinghe, R. et al. The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human sera. medRxiv, (2021).
Wang, R. et al. Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species. Immunity 54, 1611–1621.e1615 (2021).
Google Scholar
Abdelnabi, R. et al. Comparing infectivity and virulence of emerging SARS-CoV-2 variants in Syrian hamsters. EBioMedicine 68, 103403 (2021).
Google Scholar
Thorne, L. G. et al. Evolution of enhanced innate immune evasion by the SARS-CoV-2 B.1.1.7 UK variant. bioRxiv, (2021).
Kumar, A. et al. Emerging SARS-CoV-2 variants can potentially break set epidemiological barriers in COVID-19. J. Med. Virol. 94, 1300–1314 (2022).
Google Scholar
Yinda, C. K. et al. Prior aerosol infection with lineage A SARS-CoV-2 variant protects hamsters from disease, but not reinfection with B.1.351 SARS-CoV-2 variant. Emerg. Microbes Infect. 10, 1284–1292 (2021).
Google Scholar
Mohandas, S. et al. SARS-CoV-2 Delta Variant Pathogenesis and Host Response in Syrian Hamsters. Viruses 13, 1773 (2021).
Google Scholar
Brustolin, M. et al. Protection against reinfection with D614- or G614-SARS-CoV-2 isolates in golden Syrian hamster. Emerg. Microbes Infect. 10, 797–809 (2021).
Google Scholar
Gaudreault, N. N. et al. SARS-CoV-2 infection, disease and transmission in domestic cats. Emerg. Microbes Infect. 9, 2322–2332 (2020).
Google Scholar
Marsh, G. A. et al. ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets. NPJ Vaccines 6, 67 (2021).
Google Scholar
van Doremalen, N. et al. Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models. Sci. Transl. Med. 13, eabh0755 (2021).
Google Scholar
de Melo, G. D. et al. COVID-19-related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters. Sci. Transl. Med. 13, eabf8396 (2021).
Google Scholar
Allnoch, L. et al. Vascular Inflammation Is Associated with Loss of Aquaporin 1 Expression on Endothelial Cells and Increased Fluid Leakage in SARS-CoV-2 Infected Golden Syrian Hamsters. Viruses 13, 639 (2021).
Google Scholar
Becker, K. et al. Vasculitis and Neutrophil Extracellular Traps in Lungs of Golden Syrian Hamsters With SARS-CoV-2. Front. Immunol. 12, 640842 (2021).
Google Scholar
Yuan, L. et al. Gender associates with both susceptibility to infection and pathogenesis of SARS-CoV-2 in Syrian hamster. Signal Transduct. Target Ther. 6, 136 (2021).
Google Scholar
Takahashi, T. et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature 588, 315–320 (2020).
Google Scholar
Rydyznski Moderbacher, C. et al. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. Cell 183, 996–1012.e1019 (2020).
Google Scholar
Frieman, M. B. et al. SARS-CoV pathogenesis is regulated by a STAT1 dependent but a type I, II and III interferon receptor independent mechanism. PLoS Pathog. 6, e1000849 (2010).
Google Scholar
Vijay, R. et al. Critical role of phospholipase A2 group IID in age-related susceptibility to severe acute respiratory syndrome-CoV infection. J. Exp. Med. 212, 1851–1868 (2015).
Google Scholar
Bajaj, V. et al. Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections? Front. Physiol. 11, 571416 (2020).
Google Scholar
Speranza, E. et al. Age-related differences in immune dynamics during SARS-CoV-2 infection in rhesus macaques. Life Sci. Alliance 5, e202101314 (2022).
Google Scholar
Ma, Y. et al. SARS-CoV-2 infection aggravates chronic comorbidities of cardiovascular diseases and diabetes in mice. Anim. Model Exp. Med 4, 2–15 (2021).
Google Scholar
Blutt, S. E. & Estes, M. K. Organoid Models for Infectious Disease. Annu. Rev. Med. 73, 167–182 (2022).
Google Scholar
Han, Y. et al. Identification of SARS-CoV-2 inhibitors using lung and colonic organoids. Nature 589, 270–275 (2021).
Google Scholar
Matsuyama, S. et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc. Natl Acad. Sci. USA 117, 7001–7003 (2020).
Google Scholar
McCracken, K. W., Howell, J. C., Wells, J. M. & Spence, J. R. Generating human intestinal tissue from pluripotent stem cells in vitro. Nat. Protoc. 6, 1920–1928, (2011).
Google Scholar
Garcez, P. P. et al. Zika virus impairs growth in human neurospheres and brain organoids. Science 352, 816–818 (2016).
Google Scholar
Qian, X. et al. Brain-Region-Specific Organoids Using Mini-bioreactors for Modeling ZIKV Exposure. Cell 165, 1238–1254 (2016).
Google Scholar
Watanabe, M. et al. Self-Organized Cerebral Organoids with Human-Specific Features Predict Effective Drugs to Combat Zika Virus Infection. Cell Rep. 21, 517–532 (2017).
Google Scholar
Song, E. et al. Neuroinvasion of SARS-CoV-2 in human and mouse brain. J. Exp. Med. 218, e20202135 (2021).
Google Scholar
Clevers, H. Modeling Development and Disease with Organoids. Cell 165, 1586–1597 (2016).
Google Scholar
Wong, F., de la Fuente-Nunez, C. & Collins, J. J. Leveraging artificial intelligence in the fight against infectious diseases. Science 381, 164–170 (2023).
Google Scholar
Huang, R. et al. Biological activity-based modeling identifies antiviral leads against SARS-CoV-2. Nat. Biotechnol. 39, 747–753 (2021).
Google Scholar
Chen, H. et al. Systematic evaluation of machine learning methods for identifying human-pathogen protein-protein interactions. Brief. Bioinform 22, bbaa068 (2021).
Google Scholar
Hie, B., Zhong, E. D., Berger, B. & Bryson, B. Learning the language of viral evolution and escape. Science 371, 284–288 (2021).
Google Scholar
Bojar, D., Powers, R. K., Camacho, D. M. & Collins, J. J. Deep-Learning Resources for Studying Glycan-Mediated Host-Microbe Interactions. Cell Host Microbe 29, 132–144.e133 (2021).
Google Scholar
Fisch, D. et al. Defining host-pathogen interactions employing an artificial intelligence workflow. Elife 8, e40560 (2019).
Google Scholar
Lv, H. et al. Application of artificial intelligence and machine learning for COVID-19 drug discovery and vaccine design. Brief. Bioinform. 22, bbab320 (2021).
Google Scholar
Cardillo, A. G. et al. Towards in silico Process Modeling for Vaccines. Trends Biotechnol. 39, 1120–1130 (2021).
Google Scholar
Mullowney, M. W. et al. Artificial intelligence for natural product drug discovery. Nat. Rev. Drug Discov. 22, 895–916 (2023).
Google Scholar
Schadt, E. E., Friend, S. H. & Shaywitz, D. A. A network view of disease and compound screening. Nat. Rev. Drug Discov. 8, 286–295 (2009).
Google Scholar
Vatansever, S. et al. Artificial intelligence and machine learning-aided drug discovery in central nervous system diseases: State-of-the-arts and future directions. Med. Res. Rev. 41, 1427–1473 (2021).
Google Scholar
Cumming, J. G. et al. Chemical predictive modelling to improve compound quality. Nat. Rev. Drug Discov. 12, 948–962 (2013).
Google Scholar
Gleeson, M. P., Hersey, A., Montanari, D. & Overington, J. Probing the links between in vitro potency, ADMET and physicochemical parameters. Nat. Rev. Drug Discov. 10, 197–208 (2011).
Google Scholar
Singhal, D. & Curatolo, W. Drug polymorphism and dosage form design: a practical perspective. Adv. Drug Deliv. Rev. 56, 335–347, (2004).
Google Scholar
Sánchez-Valle, J. & Valencia, A. Molecular bases of comorbidities: present and future perspectives. Trends Genet 39, 773–786 (2023).
Google Scholar
Perico, L. et al. Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. Nat. Rev. Nephrol. 17, 46–64 (2021).
Google Scholar
Bowen, E. T. et al. Ebola haemorrhagic fever: experimental infection of monkeys. Trans. R. Soc. Trop. Med. Hyg. 72, 188–191 (1978).
Google Scholar
Sword, J. et al. Computed Tomography Imaging for Monitoring of Marburg Virus Disease: a Nonhuman Primate Proof-Of-Concept Study. Microbiol. Spectr. 11, e0349422 (2023).
Google Scholar
Cross, R. W. et al. Combination therapy protects macaques against advanced Marburg virus disease. Nat. Commun. 12, 1891 (2021).
Google Scholar
Carbonnelle, C. et al. Natural History of to Support Medical Countermeasure Development. Vaccines 10, 963 (2022).
Google Scholar
Warren, T. K. et al. Delayed Time-to-Treatment of an Antisense Morpholino Oligomer Is Effective against Lethal Marburg Virus Infection in Cynomolgus Macaques. PLoS Negl. Trop. Dis. 10, e0004456 (2016).
Google Scholar
Jiang, Y. et al. MERS-CoV infection causes brain damage in human DPP4-transgenic mice through complement-mediated inflammation. J. Gen. Virol. 102, 001667 (2021).
Google Scholar
Bryche, B. et al. Massive transient damage of the olfactory epithelium associated with infection of sustentacular cells by SARS-CoV-2 in golden Syrian hamsters. Brain Behav. Immun. 89, 579–586 (2020).
Google Scholar
Zhang, A. J. et al. Severe Acute Respiratory Syndrome Coronavirus 2 Infects and Damages the Mature and Immature Olfactory Sensory Neurons of Hamsters. Clin. Infect. Dis. 73, e503–e512 (2021).
Google Scholar
Zhao, Y. et al. Ferrets: A powerful model of SARS-CoV-2. Zool. Res. 44, 323–330 (2023).
Google Scholar
Zhu, Y. et al. Lymphocyte cell population as a potential hematological index for early diagnosis of COVID-19. Cell Mol. Biol. 66, 202–206 (2020).
Google Scholar
Ware, L. B. & Matthay, M. A. The acute respiratory distress syndrome. N. Engl. J. Med. 342, 1334–1349, (2000).
Google Scholar
Sinovac. Sinovac Receives Conditional Marketing Authorization in China for its COVID-19 Vaccine (Sinovac, 2021).
Castelli, J. M. et al. Effectiveness of mRNA-1273, BNT162b2, and BBIBP-CorV vaccines against infection and mortality in children in Argentina, during predominance of delta and omicron covid-19 variants: test negative, case-control study. BMJ 379, e073070 (2022).
Google Scholar
Xia, S. et al. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. JAMA 324, 951–960 (2020).
Google Scholar
Baden, L. R. et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 384, 403–416 (2021).
Google Scholar
Tai, W. et al. A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2. Cell Res. 30, 932–935 (2020).
Google Scholar
Keech, C. et al. Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N. Engl. J. Med. 383, 2320–2332 (2020).
Google Scholar
Stuart, A. S. V. et al. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. Lancet 399, 36–49 (2022).
Google Scholar
Lundgren, J. D. et al. A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19. N. Engl. J. Med. 384, 905–914 (2021).
Google Scholar
Tignor, G. H. & Hanham, C. A. Ribavirin efficacy in an in vivo model of Crimean-Congo hemorrhagic fever virus (CCHF) infection. Antivir. Res. 22, 309–325 (1993).
Google Scholar
Zivcec, M. et al. Lethal Crimean-Congo hemorrhagic fever virus infection in interferon α/β receptor knockout mice is associated with high viral loads, proinflammatory responses, and coagulopathy. J. Infect. Dis. 207, 1909–1921 (2013).
Google Scholar
Bente, D. A. et al. Pathogenesis and immune response of Crimean-Congo hemorrhagic fever virus in a STAT-1 knockout mouse model. J. Virol. 84, 11089–11100 (2010).
Google Scholar
Aligholipour Farzani, T. et al. Bovine Herpesvirus Type 4 (BoHV-4) Vector Delivering Nucleocapsid Protein of Crimean-Congo Hemorrhagic Fever Virus Induces Comparable Protective Immunity against Lethal Challenge in IFNα/β/γR−/− Mice Models. Viruses 11, 237 (2019).
Google Scholar
Ranadheera, C. et al. Characterization of a novel STAT 2 knock-out hamster model of Crimean-Congo hemorrhagic fever virus pathogenesis. Sci. Rep. 10, 12378 (2020).
Google Scholar
Haddock, E. et al. A cynomolgus macaque model for Crimean-Congo haemorrhagic fever. Nat. Microbiol. 3, 556–562 (2018).
Google Scholar
Schwarz, M. M. et al. Rift Valley Fever Virus Infects the Posterior Segment of the Eye and Induces Inflammation in a Rat Model of Ocular Disease. J. Virol. 96, e0111222 (2022).
Google Scholar
Anderson, G. W. Jr., Slone, T. W. Jr. & Peters, C. J. Pathogenesis of Rift Valley fever virus (RVFV) in inbred rats. Microb. Pathogenesis 2, 283–293 (1987).
Google Scholar
Morrill, J. C. et al. Pathogenesis of Rift Valley fever in rhesus monkeys: role of interferon response. Arch. Virol. 110, 195–212 (1990).
Google Scholar
Smith, D. R. et al. Development of a novel nonhuman primate model for Rift Valley fever. J. Virol. 86, 2109–2120 (2012).
Google Scholar
Yedloutschnig, R. J., Dardiri, A. H., Mebus, C. A. & Walker, J. S. Abortion in vaccinated sheep and cattle after challenge with Rift Valley fever virus. Vet. Rec. 109, 383–384 (1981).
Google Scholar
Rippy, M. K., Topper, M. J., Mebus, C. A. & Morrill, J. C. Rift Valley fever virus-induced encephalomyelitis and hepatitis in calves. Vet. Pathol. 29, 495–502 (1992).
Google Scholar
Morrill, J. C. et al. Rift Valley fever MP-12 vaccine elicits an early protective immune response in mice. Vaccine 40, 7255–7261 (2022).
Google Scholar
Anthony, T. et al. Vaccination with Rift Valley fever virus live attenuated vaccine strain Smithburn caused meningoencephalitis in alpacas. J. Vet. Diagn. Invest. 33, 777–781 (2021).
Google Scholar
Makoschey, B. et al. Rift Valley Fever Vaccine Virus Clone 13 Is Able to Cross the Ovine Placental Barrier Associated with Foetal Infections, Malformations, and Stillbirths. PLoS Negl. Trop. Dis. 10, e0004550 (2016).
Google Scholar
Caplen, H., Peters, C. J. & Bishop, D. H. Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development. J. Gen. Virol. 66, 2271–2277 (1985).
Google Scholar
Wichgers Schreur, P. J., Oreshkova, N., Moormann, R. J. & Kortekaas, J. Creation of Rift Valley fever viruses with four-segmented genomes reveals flexibility in bunyavirus genome packaging. J. Virol. 88, 10883–10893 (2014).
Google Scholar
Stachowiak, B. & Weingartl, H. M. Nipah virus infects specific subsets of porcine peripheral blood mononuclear cells. PloS One 7, e30855 (2012).
Google Scholar
Mungall, B. A. et al. Feline model of acute nipah virus infection and protection with a soluble glycoprotein-based subunit vaccine. J. Virol. 80, 12293–12302 (2006).
Google Scholar
Bossart, K. N. et al. A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge. Sci. Transl. Med. 4, 146ra107 (2012).
Google Scholar
Zeitlin, L. et al. Therapeutic administration of a cross-reactive mAb targeting the fusion glycoprotein of Nipah virus protects nonhuman primates. Sci. Transl. Med. 16, eadl2055 (2024).
Google Scholar
Wu, K.-Y. et al. Vertical transmission of Zika virus targeting the radial glial cells affects cortex development of offspring mice. Cell Res. 26, 645–654 (2016).
Google Scholar
Magnani, D. M. et al. Fetal demise and failed antibody therapy during Zika virus infection of pregnant macaques. Nat. Commun. 9, 1624 (2018).
Google Scholar
Hirsch, A. J. et al. Zika virus infection in pregnant rhesus macaques causes placental dysfunction and immunopathology. Nat. Commun. 9, 263 (2018).
Google Scholar
Holmes, E. C. et al. The origins of SARS-CoV-2: A critical review. Cell 184, 4848–4856 (2021).
Google Scholar
Sall, A. A. et al. Origin of 1997-98 Rift Valley fever outbreak in East Africa. Lancet 352, 1596–1597 (1998).
Google Scholar
Monath, T. P. Lassa fever: review of epidemiology and epizootiology. Bull. World Health Organ. 52, 577–592, (1975).
Google Scholar
Kindhauser, M. K. et al. Zika: the origin and spread of a mosquito-borne virus. Bull. World Health Organ. 94, 675–686c (2016).
Google Scholar
Plowright, R. K. et al. Ecological dynamics of emerging bat virus spillover. Proc. Biol. Sci. 282, 20142124 (2015).
Google Scholar
link
:max_bytes(150000):strip_icc()/hmo.asp-Final-9f9b68a2060f44c2b28782a83e14764a.jpg "What It Is, Pros and Cons")
